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A B S T R A C T
Background
There is a substantial body of evidence that prescribing for care home residents is suboptimal and requires improvement. Consequently,
there is a need to identify effective interventions to optimise prescribing and resident outcomes in this context.
Objectives
The objective of the review was to determine the effect of interventions to optimise prescribing for older people living in care homes.
Search methods
We searched the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register; Cochrane Central Register
of Controlled Trials (CENTRAL), The Cochrane Library (Issue 11, 2012); Cochrane Database of Systematic Reviews, The Cochrane
Library (Issue 11, 2012); MEDLINE OvidSP (1980 on); EMBASE, OvidSP (1980 on); Ageline, EBSCO (1966 on); CINAHL,
EBSCO (1980 on); International Pharmaceutical Abstracts, OvidSP (1980 on); PsycINFO, OvidSP (1980 on); conference proceedings
in Web of Science, Conference Proceedings Citation Index - SSH & Science, ISI Web of Knowledge (1990 on); grey literature sources
and trial registries; and contacted authors of relevant studies. We also reviewed the references lists of included studies and related reviews
(search period November 2012).
Selection criteria
We included randomised controlled trials evaluating interventions aimed at optimising prescribing for older people (aged 65 years or
older) living in institutionalised care facilities. Studies were included if they measured one or more of the following primary outcomes,
adverse drug events; hospital admissions;mortality; or secondary outcomes, quality of life (using validated instrument); medication-
related problems; medication appropriateness (using validated instrument); medicine costs.
Data collection and analysis
Two authors independently screened titles and abstracts, assessed studies for eligibility, assessed risk of bias and extracted data. A
narrative summary of results was presented.
1Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The eight included studies involved 7653 residents in 262 (range 1 to 85) care homes in six countries. Six studies were cluster-
randomised controlled trials and two studies were patient-randomised controlled trials. The interventions evaluated were diverse and
often multifaceted. Medication review was a component of seven studies, three studies involved multidisciplinary case-conferencing,
two studies involved an educational element for care home staff and one study evaluated the use of clinical decision support technology.
Due to heterogeneity, results were not combined in a meta-analysis. There was no evidence of an effect of the interventions on any
of the primary outcomes of the review (adverse drug events, hospital admissions and mortality). No studies measured quality of life.
There was evidence that the interventions led to the identification and resolution of medication-related problems. There was evidence
from two studies that medication appropriateness was improved. The evidence for an effect on medicine costs was equivocal.
Authors’ conclusions
Robust conclusions could not be drawn from the evidence due to variability in design, interventions, outcomes and results. The
interventions implemented in the studies in this review led to the identification and resolution of medication-related problems, however
evidence of an effect on resident-related outcomes was not found. There is a need for high-quality cluster-randomised controlled
trials testing clinical decision support systems and multidisciplinary interventions that measure well-defined, important resident-related
outcomes.
P L A I N L A N G U A G E S U M M A R Y
Interventions to optimise prescribing for older people in care homes
Older people living in care homes (also called nursing homes, residential homes, skilled-nursing facilities, assisted-living facilities or
aged-care facilities) have many complex physical and mental health problems. Care home residents are prescribed many medicines
compared to people who live in their own homes, with an average of eight medicines being common. International research has shown
that these medicines are often not well managed, with some residents prescribed medicines inappropriately. This has the potential to
lead to harmful side effects and a loss of benefit. For these reasons, it is important to make sure that care home residents are prescribed
the right medicines at the right doses.
This review found eight studies involving 7653 residents in 262 care homes in six countries that evaluated interventions to optimise
prescribing for care home residents. Most of the interventions had several components, often involving a review of medicines with a
pharmacist and doctor. Some interventions included a teaching component and one study used Information Technology.
There was no evidence of benefit of the interventions with respect to reducing adverse drug events (harmful effects caused bymedicines),
hospital admissions or death. None of the studies looked at quality of life. Problems relating to medicines were found and addressed
through the interventions used in the studies. Prescribing was improved based on criteria used to assess the appropriateness of prescribing
in two studies.
More high-quality studies need to be done to gather more evidence for these and other types of interventions. Further studies are
needed to evaluate new technologies, including computer systems that support prescribing decisions. More work needs to be done to
make sure that researchers are consistently measuring outcomes that are important to care home residents.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Medication review compared with usual GP care for optimising prescribing for care home residents
Patient or population: older people (aged 65 years or older) living in care homes
Settings: Institutionalised care facilities in Australia, Netherlands, Sweden, United Kingdom and USA and Canada
Intervention: Medication review as a single intervention or a component of a multi-faceted intervention
Comparison: Usual care by general practitioner
Outcomes Impact No of Participants
(studies)
Quality of the evidence
(GRADE)
Adverse drug events There was no evidence of an
effect on adverse drug events
110 in 85 care homes (1 study) ⊕⊕©©
low
Hospital admissions There was no evidence of an
effect on hospital admissions
4306 in 216 care homes (4 stud-
ies)
⊕⊕©©
low
Mortality There was no evidence of an
effect on mortality
4221 in 131 care homes (3 stud-
ies)
⊕⊕©©
low
Quality of life No studies reported quality of life 0 (no studies) -
Medication-related problems Medication review may lead to
the identification and resolution
of medication-related problems
6281 in 250 care homes (6 stud-
ies)
⊕⊕©©
low
Medication appropriateness Medication review may lead to
an improvement in medication
appropriateness
264 in 95 care homes (2 studies) ⊕⊕©©
low
Medicine costs It is uncertain whether medica-
tion review decreases medica-
tion costs
4375 in 141 care homes (4 stud-
ies)
⊕©©©
very low
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
The Gurwitz 2008 study is not included in the ’Summary of findings’ table as medication review was not a component of the intervention.
B A C K G R O U N D
Globally, the proportion of older people in the population is in-
creasing. The proportion of people aged 60 years and over was
11% in 2009 and this is projected to double by the middle of this
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century (United Nations 2009), with developed countries experi-
encing the fastest rise in number of older people. In the United
Kingdom (UK), it is estimated that by 2034 nearly a quarter of
the population will be aged 65 years and over. The most rapid rise
has been in the ’oldest old’ that is those aged 85 years and over;
it is projected that by 2034 there will be a 2.5 fold increase in
the number of the oldest old, representing 5% of the population
(Office for National Statistics 2010). As a consequence, there will
continue to be an increasing demand for long-term care across the
world.
Long-term care may be provided in people’s homes or in insti-
tutional facilities such as nursing homes or hospitals. The termi-
nology used to describe homes that provide care for older people
(defined as 65 years or older (Department of Health 2001)) differs
across the world. In the UK the homes are known as ’care homes’,
in theUnited States (US) ’long-term care facilities’ and in Australia
’aged-care facilities’. Care homes are usually classified into two
main categories, those that provide 24 hour nursing care (nursing
homes in the UK, skilled-nursing facilities in the US and aged-
care facilities providing high-level care in Australia); and those that
provide personal care (residential homes in the UK, assisted-liv-
ing in the US and aged-care facilities providing low-level care in
Australia). Some care homes provide both types of care.
Older people living in care homes are often frail, and they are
one of the most vulnerable groups in society. They have com-
plex health needs due to multiple co-morbidities and age-related
changes in pharmacokinetics and pharmacodynamics (Armour
2002). Polypharmacy, usually defined as greater than four or more
medicines (Department of Health 2001; Rollason 2003; Patterson
2012), is common in this setting across the world with residents
prescribed an increasing number of medicines over the last decade
or so. In the UK, the mean number of medicines prescribed per
resident was 4.9 in 1998 (Furniss 2000), 6.9 in 2003 (Zermansky
2006), and by 2007 this had risen to 8.0 (Barber 2009). Many
care home residents also have cognitive impairment and this can
impede their ability to communicate medicine-related problems
(Matthews 2002; Alldred 2007a).
The complexity of prescribing for this population is compounded
by multiple clinicians prescribing. This may involve family physi-
cians and community-based consultants (for example old age psy-
chiatrists and geriatricians) in primary care; and secondary care
doctors frommultiple specialties. In addition, the lack of represen-
tation of older people in clinical trials limits the evidence base and
further increases the complexity (Beglinger 2008). It is, therefore,
perhaps unsurprising that there is extensive evidence that prescrib-
ing is suboptimal for care home residents. Inappropriate prescrib-
ing, measured using validated, explicit and implicit definitions,
has been found to be common in nursing and residential homes
in several countries including the US (Beers 1992; Hanlon 1996;
Sloane 2002; Gray 2003; Lau 2005; Perri 2005), Canada (Brymer
2003), the UK (Oborne 2003) and Australia (Crotty 2004).
Perri 2005 found that over a one month duration, 47% of 1117
residents of 15 US nursing homes received at least one inappro-
priate medicine, with 13% of residents having at least one adverse
health outcome. Inappropriate prescribing more than doubled the
risk of a resident experiencing at least one adverse health outcome
(odds ratio (OR) 2.34, 95% confidence interval (CI) 1.61-3.40).
Lau 2005 reported that 50% of 3372 US nursing home residents
were prescribed at least one inappropriate medicine over one year.
The risks of hospitalisation and death were greater in those resi-
dents exposed to an inappropriate medicine (OR 1.27, 95% CI
1.09-1.47; OR 1.28, 95% CI 1.05-1.55, respectively). Gray 2003
found that 22% of 282 US residents of residential care facilities
were prescribed at least one inappropriate medicine. There is also
evidence that care home residents are under-prescribed benefi-
cial drugs and are poorly monitored with respect to their long-
term conditions and their medicines (Fahey 2003; Alldred 2007b;
Barber 2009).
For the reasons discussed above, care home residents are particu-
larly susceptible to adverse drug events. In two US long-term care
facilities, Gurwitz 2005 found 9.8 adverse drug events per 100
resident-months, with 42% being judged as preventable. Drug-
related problems have been found to be responsible for 3% to 31%
of hospital admissions of older people, and up to half of these are
potentially avoidable (Howard 2007).
Description of the condition
As described above, suboptimal prescribing for older people liv-
ing in care homes is common and may occur due to the pre-
scribing of inappropriate medicines, the omission of beneficial
medicines or the failure to appropriately monitor residents and the
effects of their medicines. There are a variety of instruments that
can be employed to measure the appropriateness of prescribing in
older people (Spinewine 2007). However, the predictive validity of
these instruments on health outcomes such as adverse drug events
and hospital admissions has not been unequivocally established
(Spinewine 2007).
Description of the intervention
For this review, wewere interested in interventions concerned with
optimising the whole medication regime for care home residents,
not those concentrating solely on isolated drugs or classes such as
benzodiazepines or antipsychotics nor those concentrating on one
disease state. Financial and regulatory interventions tend to fall
into this latter category.
There are several types of interventions that can potentially opti-
mise prescribing in this setting, including:
• professional interventions, for example educational
programmes aimed at prescribers;
4Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• organisational interventions, for example medication review
services or specialist clinics, case conferencing, information and
communication technology (ICT) interventions such as clinical
decision support systems.
Medication review interventions may be aimed at specific drugs or
the whole regime and can be uni- or multiprofessional, involving
physicians, nurses and pharmacists.
How the intervention might work
Interventions designed to improve prescribing for care home res-
idents may have an impact by discontinuing inappropriate med-
ication; commencing beneficial medicines; and ensuring appro-
priate monitoring of long-term conditions and medicines. Con-
sequently, this may lead to a reduction in adverse drug events,
improved quality of life and a reduction in medicine costs.
Why it is important to do this review
There is a substantial body of evidence that prescribing for care
home residents is suboptimal and requires improvement. As well,
there are other Cochrane reviews being undertaken which address
similar issues in different populations (Soe 2009; Christensen
2011). We evaluated the evidence for interventions to address
suboptimal prescribing in this setting to identify how care can be
improved for this frail and vulnerable population. We intended
to achieve this by determining which interventions were effective
and by identifying gaps in the evidence to inform future research.
O B J E C T I V E S
The objective of the review was to determine the effect of inter-
ventions to optimise overall prescribing for older people living in
care homes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included patient-randomised controlled trials (P-RCT) and
cluster-randomised controlled trials (C-RCT).
Types of participants
We included studies of older people (aged 65 years or older) living
in institutionalised care facilities. Institutionalised care facilities
include: nursing homes and residential homes (UK); skilled-nurs-
ing facilities and assisted-living facilities (US); and aged-care fa-
cilities providing low-level and high-level care (Australia). If there
was any ambiguity in the description of the institution, we clari-
fied this with the authors of relevant papers. We considered trials
for inclusion if they had a majority (80% or more) of participants
aged 65 years or more, or if themean age was greater than 65 years.
We excluded studies where the intervention focused on a single
medical condition or a specific drug or class of drugs. We also ex-
cluded studies where the main focus was to reduce medication er-
rors because such studies have a narrow focus and do not consider
the whole medication regime. In addition, they do not seek to
optimise prescribing, for example by adhering to evidence-based
guidelines or by reducing inappropriate prescribing, but are de-
signed to solely reduce errors.
Types of interventions
We assessed interventions aimed at optimising prescribing for care
home residents compared with usual care as defined by the study.
These interventions potentially included: educational interven-
tions aimed at prescribers; medication review services (uni or mul-
tiprofessional, conducted by nurses, pharmacists or physicians);
case conferencing; and ICT interventions such as clinical decision
support systems. We excluded financial and regulatory interven-
tions.
Types of outcome measures
We included a range of outcome measures including patient-re-
lated outcomes, health service utilisation, and economic outcomes.
Studies were included if they reported at least one primary out-
come measure or at least one secondary outcome measure.
Primary outcomes
The primary outcome measures for the review were:
1. adverse drug events;
2. hospital admissions;
3. mortality.
Secondary outcomes
Secondary outcome measures were:
1. quality of life (using validated instrument);
2. medication-related problems;
3. medication appropriateness (using validated instrument);
4. medicine costs.
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Search methods for identification of studies
Pat Spoor developed the search strategies in consultation with the
other authors and with Michelle Fiander, Trials Search Co-ordi-
nator (TSC) for the EPOC Group. We searched the Cochrane
Database of Systematic Reviews (Issue 11, 2012) for related sys-
tematic reviews, and the databases listed below for primary studies.
Searches were conducted in November 2012. Exact search dates
for each database are included with the search strategies in Ap-
pendix A. When we conducted the scoping searches to prepare for
this systematic review, we did not identify any studies for inclu-
sion prior to 1980. Also, since 1980 the care of older people in in-
stitutionalised facilities has changed significantly due to residents
having greater levels of morbidity with an increase in polyphar-
macy, leading to greater complexity of care. For these reasons, we
searched for studies from 1980 onwards to ensure we had studies
of relevance to contemporary practice.
Electronic searches
• Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library (Issue 11, 2012)
• EPOC Group Specialised Register, Reference Manager
• MEDLINE, OvidSP (1980 on)
• EMBASE, OvidSP (1980 on)
• Ageline, EBSCO (1966 on)
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), EBSCO (1980 on)
• International Pharmaceutical Abstracts, OvidSP (1970 on)
• PsycINFO, OvidSP (1980 on)
• Web of Science, Conference Proceedings Citation Index -
SSH (ISI Web of Knowledge) (1990 on)
• Web of Science, Conference Proceedings Citation Index -
Science (ISI Web of Knowledge) (1990 on)
Search strategies were comprised of keywords and, when available,
controlled vocabulary such as MeSH (Medical Subject Headings).
The finalised search strategies were developed using an iterative de-
velopment process in which citations identified by various search
terms were screened for relevance by the information specialist. In
this manner, individual terms and combinations of terms were as-
sessed as relevant or irrelevant and were included or omitted from
the final search strategies. No language restrictions were used. All
databases were searched from 1980 on with the exception of Age-
line, which was run from 1966 on, and Web of Science Confer-
ence Proceedings indices which were searched from 1990 on.
A Cochrane filter was used to identify RCTs in MEDLINE (
Lefebvre 2011). All search strategies, as run, are provided in
Appendix 1.
Searching other resources
Grey literature
We conducted a grey literature search to identify studies not in-
dexed in the databases listed above, using the following source:
• Google Scholarscholar.google.com.
For search terms and number of results, see Appendix 2.
Trials registries
• International Clinical Trials Registry Platform (ICTRP),
World Health Organization (WHO) (http://www.who.int/ictrp/
en/)
For search terms and number of results, see Appendix 3.
We also:
• reviewed reference lists of all included studies, relevant
systematic reviews and primary studies;
• contacted authors of relevant studies to clarify reported
published information.
Data collection and analysis
Selection of studies
Two review authors (DPA andDKR) independently screened titles
and abstracts to decide which studies met the inclusion criteria.
Any papers not meeting the inclusion criteria were excluded at
this stage. If there was uncertainty or disagreement, consensus was
reached by discussion with co-review authors. Two review authors
(DA and DKR) independently assessed the full text articles to
ensure they still met the inclusion criteria. Full text articles not
published in English were translated prior to being assessed for
inclusion.
Data extraction and management
Two review authors (DPA and DKR) independently extracted de-
tails of articles included in the review, including the study design,
the study population, the intervention, usual care, outcome mea-
sures used and length of follow-up data, using a specially designed
data extraction form based on the EPOC template (EPOC 2009).
Where necessary, we contacted authors for missing information
or clarification. We intended to use information from the data
extraction forms to guide extraction of numerical data for meta-
analysis in Review Manager 5 (RevMan 2008). We intended to
present data from P-RCTs and C-RCTs using the format in the
EPOC working paper on presentation of data (EPOC 2009).
6Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of risk of bias in included studies
The internal validity of each included study was assessed by two
review authors (DPA and DKR). We used The Cochrane Collab-
oration’s tool for assessing risk of bias (Higgins 2008) based on six
standard criteria: adequate sequence generation; concealment of
allocation; blinded or objective assessment of primary outcome(s);
adequately addressed incomplete outcome data; freedom from se-
lective reporting; freedom from other risk of bias. We used four
additional criteria specified by EPOC (EPOC2009): similar base-
line outcome measurements; similar baseline characteristics; reli-
able primary outcome measures; and adequate protection against
contamination. We assessed and reported all included studies in
the Cochrane ‘Risk of bias’ tables.
Assessment of the quality of the evidence
The quality of the evidence was assessed using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) criteria (GRADE 2012).
Measures of treatment effect
We initially planned to conduct a meta-analysis, however, this
was not possible due to heterogeneity (see Results). Therefore, we
presented a narrative summary of the results. Wherever possible,
we presented results with 95% confidence intervals.
Unit of analysis issues
We critically examined the methods of analysis of all study types.
We may have identifed C-RCTs with unit of analysis errors (for
example, randomisation by care home with analysis by residents
without adjustments for clustering). If unit of analysis issues had
been found, we intended to attempt to re-analyse the data and
report the intra-cluster correlation co-efficient and adjust for clus-
tering if possible. However, no unit of analysis errors were identi-
fied.
Dealing with missing data
We intended to exclude studies from a meta-analysis if there was
differential loss to follow-up between groups, greater than 20%.
However, as meta-analysis was not appropriate this did not apply.
Assessment of heterogeneity
See Data synthesis section.
Assessment of reporting biases
We intended to examine funnel plots corresponding tometa-anal-
ysis of the primary outcome in order to assess the potential for
small study effects such as publication bias. However, this was not
possible as meta-analysis was not undertaken.
Data synthesis
We intended to synthesise the results of the studies depending on
the quality, design and heterogeneity, and we intended to pool
the results of studies if at least two studies were homogeneous
regarding the participants, interventions and outcomes. As stated
above, this was not possible and, therefore, a narrative summary
was undertaken. We described studies according to setting, type
of intervention and study design together with an assessment of
the evidence on the theoretical basis for each of the approaches
described.
Subgroup analysis and investigation of heterogeneity
We intended to conduct subgroup analyses for professional and
organisational interventions where possible. If we had found that
one type of intervention was common, for example medication
review, we intended to analyse this separately. If possible, we also
planned to undertake subgroup analyses based on the specific na-
ture of the intervention, for example pharmacist-led medication
review. However, subgroup analyses were not possible due to het-
erogeneity.
See Data synthesis section for the investigation of heterogeneity.
Sensitivity analysis
We intended toperform sensitivity analysis for pooled results based
on the risk of bias. However, as we could not pool results this did
not apply.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of ongoing
studies.
See: Characteristics of included studies; Characteristics of ongoing
studies; Table 1
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Results of the search
The search strategy identified 6985 articles for potential inclusion.
Following independent screening of titles and abstracts by DPA
and DKR, 48 full text articles were assessed for eligibility and
eight studies met the inclusion criteria. Two studies are awaiting
classification (Beer 2011; Lapane 2011). See Figure 1 (PRISMA
flowchart) for details. The search yielded five related systematic
reviews (Kaur 2009; Ostini 2009; Verrue 2009; LaMantia 2010;
Loganathan 2011) and one narrative review (Markum 2010) and
their references were reviewed; no further relevant studies were
identified from these.
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Figure 1. Study flow diagram.
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Included studies
The eight included studies involved 7653 residents in 262 (range
1 to 85) care homes. Three studies were conducted in Australia
(Roberts 2001; Crotty 2004a; Crotty 2004b), two in the UK (
Furniss 2000; Zermansky 2006), one in Sweden (Claesson 1998),
one in the Netherlands (Strikwerda 1994) and one in the USA
and Canada (Gurwitz 2008).
Design
Six studies were C-RCTs (Strikwerda 1994; Claesson 1998;
Furniss 2000; Roberts 2001; Crotty 2004a; Gurwitz 2008) and
two studies were P-RCTs (Crotty 2004b; Zermansky 2006). There
was a wide range of study duration and follow-up between the
studies, ranging from six weeks to two years (see Table 1).
Participants
All studies involved older people living in care homes (long-term
care facilities). Mean age ranged from 81.2 years (Furniss 2000)
to 87.2 years (Gurwitz 2008) and the majority of residents were
female (range 59.7% (Crotty 2004a) to 77% (Zermansky 2006)).
The study by Roberts 2001 did not report mean age or gender.
Strikwerda 1994 studied 196 residents in one nursing home,
Claesson 1998 studied 1854 residents in 33 nursing homes, Crotty
2004a studied 154 residents in 10 high-level residential facilities,
Crotty 2004b studied 110 residents in 85 long-term care facilities,
Furniss 2000 studied 330 residents in 14 nursing homes, Gurwitz
2008 studied 1118 residents in 29 units in two long-term care fa-
cilities, Roberts 2001 studied 3230 residents in 52 nursing homes
and Zermansky 2006 studied 661 residents in 65 nursing and res-
idential homes for older people.
Interventions
The interventions evaluated were diverse and often multifaceted.
Medication review (conducted by various methods) was a com-
ponent of seven studies (Strikwerda 1994; Claesson 1998; Furniss
2000; Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky
2006). Three studies involved multidisciplinary case-conferenc-
ing (Claesson 1998; Crotty 2004a; Crotty 2004b) and two stud-
ies involved an educational element for care home staff (Roberts
2001; Crotty 2004a). One study evaluated the use of clinical de-
cision support technology (Gurwitz 2008). Other components
of interventions included introducing a new professional role to
stakeholders (Roberts 2001) and the transfer of medicines infor-
mation (Crotty 2004b). Further descriptions of interventions are
presented below.
Strikwerda 1994 evaluated the effect of community pharmacist
feedback to GPs on their patients’ prescriptions over a four week
period.
Claesson 1998 evaluated the effectiveness of monthly multidis-
ciplinary team meetings between the physician, pharmacist and
nurse(s) over 12 months. The aim of the meetings was to discuss
and improve the use of drugs. Pharmacists received a total of 65.5
hours of education and training prior to and during the interven-
tion period.
Furniss 2000 investigated the effectiveness of pharmacist-con-
ducted medication review (in addition to usual care by the GP)
versus usual care by the GP. The intervention was a single med-
ication review conducted by one pharmacist with access to med-
ical and nursing home records. No details were provided on the
education and training of the pharmacist.
The intervention evaluated by Roberts 2001 had three compo-
nents: (i) introducing a new professional role and relationship
building; (ii) nurse education; (iii) medication review by pharma-
cists holding a postgraduate diploma in clinical pharmacy. Med-
ication reviews were undertaken for a non-random subsample of
500 residents (total intervention residents 905) selected by nurs-
ing staff. Most of the contact between pharmacists and GPs was
indirect.
Crotty 2004a evaluated the effectiveness of an ’outreach medica-
tion advisory service’. This involved a medication review prepared
by the pharmacist, followed by two multidisciplinary case confer-
ences held six to 12 weeks apart (with the GP, geriatrician, phar-
macist, care staff and an Alzheimer’s Association of South Australia
representative). No details were provided on the education and
training of the pharmacist.
Crotty 2004b investigated the effectiveness of a pharmacist tran-
sition co-ordinator for residents who were being discharged from
hospital to a long-term care facility. The intervention focused on
the transfer of medicines information to the nursing home staff,
GP and the community pharmacist. Following this, a medication
review was conducted by the community pharmacist contracted
to the care home. In addition, the transition pharmacist co-or-
dinated a multidisciplinary case conference 14 to 28 days after
transfer involving him or herself, the GP, community pharmacist
and a nurse.
Zermansky 2006 evaluated the effectiveness of a clinical medica-
tion review (in addition to usual care by the GP) undertaken by
a pharmacist who held a post-graduate clinical pharmacy qualifi-
cation versus usual care by the GP. The pharmacist reviewed the
medicines with the medical and care home records in conjunction
with a consultation with the resident (if possible) and a nurse or
carer.
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The intervention investigated by Gurwitz 2008 was a clinical de-
cision support system in facilities that had computerised provider
order entry systems. The clinical decision support system was de-
signed based on previous research on preventable adverse drug
events, criteria for suboptimal prescribing in older people and
drug-drug interactions. Warning messages were displayed to pre-
scribers in a pop-up box in real time when medicines were entered
into the computer provider order entry system. Prescribers were
free to either act on alerts or ignore them.
Outcomes
Outcomes were diverse with differing definitions, methods of data
collection, varying time points and different reporting methods.
Studies reportedmeasures other than those specified for this review
and these are listed in theCharacteristics of included studies tables.
Primary outcome measures
Adverse drug events
Only two studies specified adverse drug events as an outcome
measure (Crotty 2004b; Gurwitz 2008). However, Crotty 2004b
did not define adverse drug events. Adverse drug events were the
primary outcome measure in the Gurwitz 2008 study and were
defined as ’an injury resulting from the use of a drug’; such adverse
drug events may have resulted from medication errors or from
adverse drug reactions in which there was no error.
Hospital admissions
Four studies included hospital admissions as an outcome measure
(Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006).
Furniss 2000 reported hospital admissions as the number of in-
patient days. Roberts 2001 reported the proportion of residents
hospitalised and Zermansky 2006 reported the mean number of
non-elective hospitalisations per resident. Crotty 2004b grouped
together emergency department visits and hospital readmissions.
Mortality
Three studies included mortality as an outcome measure (Furniss
2000; Roberts 2001; Zermansky 2006). Furniss 2000 and
Zermansky 2006 reported mortality as the number of deaths over
eight and six months, respectively. Roberts 2001 reported the pro-
portion of residents who had died over 12 months together with
cumulative survival.
Secondary outcome measures
Quality of life
No studies measured quality of life.
Medication-related problems
Medication-related problems were measured and classified in di-
verse ways in six studies. Strikwerda 1994 reported the number of
pharmacists’ recommendations and described their type. Claesson
1998 described the type and frequency of drug-related problems
along with pharmacists’ recommendations. Furniss 2000 mea-
sured the number of pharmacist’s recommendations, accepted rec-
ommendations by the GP, and the number of treatment changes.
Reasons were provided for the pharmacist’s recommendations.
Roberts 2001 measured the number of medicine changes likely to
be due to medication review. Crotty 2004b identified medication-
related problems and classified them into categories. Zermansky
2006 measured the number of changes in medication per partici-
pant as the primary outcome; pharmacist’s recommendations were
identified, collated and classified along with GPs’ acceptance of
the recommendations.
Medication appropriateness
Two studies assessed medication appropriateness using a validated
tool (Crotty 2004a; Crotty 2004b). Both studies used the Medi-
cation Appropriateness Index (MAI) (Hanlon 1992).
Medicine costs
Four studies calculated medicine costs (Furniss 2000; Roberts
2001; Crotty 2004a; Zermansky 2006). Furniss 2000 calculated
drug costs per resident throughout the observation and interven-
tion phases of the study. Roberts 2001 collected yearly drug costs
from prescription claims data based on the Australian Pharma-
ceutical Benefits Scheme. Crotty 2004a calculated monthly drug
costs for all regular medicines based on the Australian Pharmaceu-
tical Benefits Scheme. Zermansky 2006 calculated the 28 day net
ingredient cost of repeat medicines per resident.
Excluded studies
None reported.
Risk of bias in included studies
Studies were heterogeneous with regard to risk of bias (see Figure
2; Figure 3). Risk of bias is summarised below for each domain.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six studies were judged to have a low risk of bias based on random
sequence generation (Furniss 2000; Roberts 2001; Crotty 2004a;
Crotty 2004b; Zermansky 2006; Gurwitz 2008). The studies by
Strikwerda 1994 and Claesson 1998 did not report how the se-
quence was generated. Four studies utilised computer-generated
randomor pseudo-randomnumbers (Furniss 2000; Crotty 2004a;
Crotty 2004b; Zermansky 2006) and Roberts 2001 drew from
a hat. Allocation was adequately concealed via centralisation in
both of the P-RCTs (Crotty 2004b; Zermansky 2006). Due to the
remaining six studies having a cluster design, they were deemed
to be at low risk of bias with regard to allocation concealment
(Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001;
Crotty 2004a; Gurwitz 2008).
Blinding
Due to the nature of the interventions it was not possible to blind
participants and personnel in any of the studies and, therefore,
performance bias was judged to be high for each study. Three stud-
ies blinded outcome assessment for subjective outcomes (Crotty
2004a; Crotty 2004b; Gurwitz 2008) and, therefore, detection
bias for these outcomes was low for these studies and high for
the remainder. Detection bias was deemed to be low for objective
outcomes for studies that reported them.
Incomplete outcome data
Three studies were deemed at low risk of attrition bias as they
reported similar baseline characteristics with a similar number
of dropouts for similar reasons (Crotty 2004a; Crotty 2004b;
Zermansky 2006). The only outcome in the Claesson 1998 study
was a description of medicine-related problems in the interven-
tion group and attrition bias was not relevant. The risk of attri-
tion bias was unclear for four studies due to a lack of information
(Strikwerda 1994; Furniss 2000; Roberts 2001; Gurwitz 2008).
Selective reporting
Although there was no evidence of selective reporting in the stud-
ies, that is all outcome measures stated in the methods were re-
ported, research protocols were not available and, therefore, there
was insufficient information to permit judgement.
Other potential sources of bias
Similar baseline outcome measurements
Three studies (Roberts 2001; Crotty 2004b; Zermansky 2006)
were deemed at low risk of bias as baseline outcome measurements
were similar. Furniss 2000 was judged to be at high risk of bias
because there were fewer deaths in the control group compared
with the intervention group. Crotty 2004a was also judged to be at
a high risk of bias because of baseline differences in theMedication
Appropriateness Index. The three remaining studies were deemed
to be at an unclear risk of bias as outcomes were not measured at
baseline (Strikwerda 1994; Claesson 1998; Gurwitz 2008).
Similar baseline characteristics
Five studies reported similar baseline characteristics and were
judged to be at low risk of bias (Claesson 1998; Roberts 2001;
Crotty 2004a; Crotty 2004b; Zermansky 2006). The study by
Strikwerda 1994 reported fewer males in group A and fewer
medicines in group B compared to group C and was judged to
be at high risk. The study by Furniss 2000 was deemed to be at
high risk because in the control group the residents were younger
and there were fewer females. Gurwitz 2008 was deemed to be at
unclear risk because baseline characteristics of residents were not
reported (although units were matched for general characteristics,
bed size and general characteristics of residents).
Reliable primary outcome measure
All eight studies were deemed to have reliable primary outcome
measures (although not all the outcome measures were included
in this review).
Adequate protection against contamination
Two studies that were of a cluster design were assessed to be at
an unclear risk of adequate protection against contamination be-
cause although they were randomised by care home it was un-
clear whether a GP may have serviced both intervention and con-
trol homes (Claesson 1998; Roberts 2001). The study by Crotty
2004a was deemed to be at low risk of contamination because
in addition to the cluster design the GPs were checked to avoid
contamination between intervention and control residents. The
study by Strikwerda 1994 was at high risk because although resi-
dents were randomised by GP they all resided in the same nursing
home. Furniss 2000 randomised care homes in different geograph-
ical areas and was therefore deemed at low risk of contamination.
Gurwitz 2008 attempted to limit the crossover of prescribers be-
tween intervention and control units, however some prescribers
worked simultaneously on both units and consequently the trial
was judged to be at high risk of contamination. The two studies
that were P-RCTs were deemed to be at high risk as contamination
was possible (Crotty 2004b; Zermansky 2006).
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Effects of interventions
See: Summary of findings for the main comparison
Due to the heterogeneity in interventions, outcomes and risk of
bias, it was deemed inappropriate to conduct a meta-analysis. The
effectiveness of the interventions are described below.
Primary outcome measures
Adverse drug events
Crotty 2004b found no evidence of an effect of a pharmacist
transition coordinator on adverse drug events (relative risk 1.05,
95% CI 0.66 to 1.68). Gurwitz 2008 tested a clinical decision
support system and found no evidence of an effect on all adverse
drug events (adjusted rate ratio 1.06, 95% CI 0.92 to 1.23) or
preventable adverse drug events (adjusted rate ratio 1.02, 95% CI
0.81 to 1.30).
Hospital admissions
Furniss 2000 found fewer inpatient days per resident in the inter-
vention group compared with the control group during the four
month intervention phase of the study (0.55 versus 1.26); how-
ever, small numbers precluded statistical analysis. In the Roberts
2001 study, no statistically significant difference was found in the
mean proportion of residents hospitalised between the interven-
tion and control groups. Crotty 2004b demonstrated a reduction
in the combination of emergency room visits and hospital read-
missions with a relative risk ratio of 0.38 (95% CI 0.15 to 0.99)
when analysing residents who were alive at follow-up. When res-
idents who had died were included, there was no evidence of an
effect on hospital admissions (relative risk 0.58, 95% CI 0.28 to
1.21). Zermansky 2006 showed no evidence of an effect on the
mean number of hospitalisations per resident (relative risk 0.75,
95% CI 0.52 to 1.07).
Mortality
Furniss 2000 found fewer deaths in the intervention group com-
pared with the control group during the intervention phase of the
study (4 versus 14, P = 0.028); however when the observation
phase of the study was taken into account, the number of deaths
in the control and intervention groups were 28 and 26 (P value
not reported), respectively. In the Roberts 2001 study, no statis-
tically significant difference was found in the mean proportion
of residents who had died between the intervention and control
groups. A survival analysis found a hazard ratio of 0.85 (95% CI
0.75 to 0.96) in favour of the intervention group when analysed by
individual residents; however after accounting for the clustering
effect this was no longer statistically significant (hazard ratio 0.85,
95% CI 0.68 to 1.06). Zermansky 2006 showed no evidence of
an effect on the number of deaths (relative risk 1.06, 95% CI 0.70
to 1.64).
Secondary outcome measures
Quality of life
No studies evaluated the effect of interventions on this outcome.
Medication-related problems
Strikwerda 1994 reported that 122 potential medication-related
problems were identified in 61 residents. As a result, nine
medicines were discontinued and four medicines had a dose re-
duction. The most common medication-related problem was a
potential interaction (51, 42%), followed by dose (31, 25%), in-
dication (23, 19%) and duration of the prescription (17, 14%).
Claesson 1998 identified 819 drug-related problems in 395 resi-
dents (2.1 per resident). The most common problem was ’choice
of drug’ (348, 43%), with the majority of these being inappro-
priate according to Swedish Medical Product Agency guidelines.
Two hundred and seventy-six (34%) problems were due to ’un-
clear indication’ whereby the team did not know why a drug had
been prescribed or the drug had not been adequately re-evalu-
ated. Ninety per cent (737) of the problems discussed were acted
upon, with 368 (45%) resulting in stopping the medicine and 162
(20%) led to a change of medicine. Five hundred and thirty-two
medicine changes were evaluated with 404 (76%) still in place
after a month, 59 (11%) discontinued and previous therapy room
restored, and 69 (13%) were difficult to evaluate as partial changes
had occurred.
Furniss 2000 made 261 recommendations of which 239 (92%)
were accepted by the GP. This resulted in 144 actual treatment
changes. Thirty residents did not require a change in therapy, and
themean number of recommendations per resident (for those who
needed at least one recommendation) was 2.46 (range 0 to 7). The
most common reasons for recommendations were ’indication for
the medication no longer present’ (85, 33%) and ’safer or more
efficacious use of drug’ (77, 30%).
Roberts 2001 followed up 137 of the 500 medication reviews
conducted and found that 54 (39%) of the residents had changes
likely to be due to the review.No further informationwas provided.
Crotty 2004b identified medicine-related problems at admission
to the long-term care facility for intervention and control resi-
dents. The most common issue classified as a medicine-related
problem by the authors was that a resident had been appointed a
new physician. The next most common problems identified were:
discrepancy between medication discharge summary and medica-
tion (32, 57% intervention; 26, 48% control); precaution with
use (18, 32% intervention; 14, 26% control); no indication for
medication (18, 32% intervention; 8, 15% control).
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In the study by Zermansky 2006, at least one recommendation
was made in 256 (77%, 95% CI 73.1 to 81.7) residents, with a
mean of 2.3 recommendations per resident. Six hundred and sev-
enty-two medication-related recommendations were made along
with an additional 75 recommendations related to the residents’
conditions. The most common recommendation was technical
(for example generic switching, amending quantities, removing
discontinued items from the repeat prescription) with 225 (30%)
recommendations. Following technical reasons, themost common
recommendations were to conduct a test to monitor therapy (161,
22%) and to stop a medicine (100, 13%). The GP accepted 565
(76%) of the pharmacist’s recommendations and rejected 52 (7%);
there was no response to the review or the resident died before the
review could be actioned in the remaining cases. The GP actioned
433 (77%) of the accepted recommendations.
Medication appropriateness
Crotty 2004a found that, based on the Medication Appropriate-
ness Index (MAI), medication appropriateness improved in the
intervention group (MAI mean change 4.1, 95% CI 2.1 to 6.1)
compared with the control group (MAI mean change 0.4, 95%CI
-0.4 to 1.2). MAI scores were higher at baseline for intervention
group residents compared with control residents (mean MAI 7.4,
95% CI 4.5 to 10.3 versus 4.1, 95% CI 2.4 to 5.7). There were no
baseline differences in meanMAI scores between the control (3.7,
95% CI 2.2 to 5.2) and intervention groups (3.2, 95% CI 1.8 to
4.6) in the Crotty 2004b study. Following the intervention, there
was no change in MAI in the intervention group (2.5, 95% CI
1.4 to 3.7) whereas the MAI in the control group had worsened
(6.5, 95% CI 3.9 to 9.1). The difference in MAI scores at follow-
up was statistically significant (P = 0.007). The effect of the inter-
vention on MAI scores remained significant when controlled for
baseline MAI, Charlson Comorbidity Index and the number of
drugs discontinued during hospital admission.
Medicine costs
The cost of medicines per resident in the observation phase of the
Furniss study was £142.53 in the control group and £159.01 in
the intervention group (Furniss 2000). Following the intervention
phase, costs were £141.24 in the control group versus £131.54
in the intervention group, representing a reduction in medicine
costs of £27.47 per resident over a four month period. Accounting
for the pharmacist’s time, the cost saving on medicines in the
intervention group was calculated to be £22/resident. Roberts
2001 calculated a drug cost saving of $AU64 per resident per
year in the intervention group compared to the control group.
When the cost of the intervention was accounted for, the net
cost saving was $AU16 per resident per year. Crotty 2004a found
no statistically significant difference in mean medicine costs per
month per resident between the intervention and control groups
(mean change $AU5.72 intervention versus $AU3.37 control, P
= 0.837). Zermansky 2006 found no evidence of an effect of the
intervention on the cost of 28 days repeat medicines per resident
(mean difference £ -0.70, 95% CI £-7.28 to £5.71).
D I S C U S S I O N
Summary of main results
Eight studies were included in the review and one ongoing study.
There was no evidence of an effect of the interventions on any
of the primary outcomes of the review that is adverse drug events
(Crotty 2004b;Gurwitz 2008), hospital admissions (Furniss 2000;
Roberts 2001; Crotty 2004b; Zermansky 2006) and mortality
(Furniss 2000; Roberts 2001; Zermansky 2006). No studies in-
cluded quality of life measures. There was evidence that the in-
terventions led to the identification and resolution of medica-
tion-related problems (Strikwerda 1994; Claesson 1998; Furniss
2000; Roberts 2001; Crotty 2004b; Zermansky 2006). There was
evidence from two studies that medication appropriateness was
improved (Crotty 2004a; Crotty 2004b). However, the link be-
tween improved medication appropriateness based on the Medi-
cation Appropriateness Index and patient-related outcomes is not
clear. The evidence for an effect on medicine costs was equivo-
cal with two studies finding a reduction in costs (Furniss 2000;
Roberts 2001) and two studies finding no difference (Crotty
2004a; Zermansky 2006).
Overall completeness and applicability of
evidence
The review was designed to identify interventions that consid-
ered residents’ whole medication regimens to optimise prescrib-
ing. Consequently, a broad range of interventions (professional
and organisational) were eligible for the review and diverse, multi-
faceted interventions were ultimately implemented to address the
objectives of the review.
The interventions were tested in the population of interest; how-
ever, there was considerable variability in the outcomes measured
with quality of life not represented in any of the included studies.
Current practice varies considerably internationally. However,
multidisciplinary teams (involving physicians, nurses and phar-
macists) play a significant role in optimising prescribing for care
home residents and this was reflected in the studies; the majority
of interventions involved multidisciplinary teamworking, usually
with pharmacists conducting medication reviews. However, the
effectiveness of this has not been demonstrated. Information and
communication technology is increasingly being employed to op-
timise prescribing in many settings, and one study tested the im-
pact of a clinical decision support system (Gurwitz 2008).
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Quality of the evidence
Robust conclusions cannot be drawn from the evidence due to
variability in design, interventions, outcomes and results. The re-
view included eight studies of varying quality that included 7653
residents living in 262 care homes in six countries. As medication
review was the main intervention or a component of the inter-
vention in seven out of the eight studies, the effects of medica-
tion review were summarised in the ’Summary of findings’ table
(Summary of findings for themain comparison). The overall qual-
ity of the evidence for the outcomes reported was low or very low.
The majority of the included studies were cluster-RCTs and this
was appropriate given the complex nature of interventions, the
difficulty of blinding and the consequential threat of contamina-
tion. The patient-RCTs did not adequately protect against con-
tamination and, therefore, the effects of the intervention may have
potentially been diluted. Some of the studies had short follow-
up periods, which may have potentially limited the detection of
effects on outcomes. None of the studies blinded participants and
personnel, however this was unlikely to have been achievable due
to the nature of the interventions. The interventions tested were
complex and multifaceted and none of the studies attempted to
disentangle the ’black box’ effect, that is to understand the effects
of the contributing components. Not all the studies attempted
blinding of assessment for subjective outcomes, and this could
have been implemented. A major limitation of the evidence was
the diversity of outcome measures and the fact that they differed
in the way they were defined (if at all), collected and analysed.
Potential biases in the review process
Bias was minimised when conducting this review by several meth-
ods. An extensive literature search was conducted which was
guided by EPOC and the included studies from published system-
atic reviews were screened. Studies were not limited to those in
the English language. Two review authors independently screened
titles and abstracts, assessed studies for eligibility, evaluated risk of
bias and extracted data.
Agreements and disagreements with other
studies or reviews
Five previously published systematic reviews (Kaur 2009; Ostini
2009; Verrue 2009; LaMantia 2010; Loganathan 2011) and one
narrative review (Markum 2010) related to the objectives of this
review were identified. No further studies were identified from
these reviews and the conclusions were similar, that is mixed re-
sults were obtained from the several intervention types tested in
heterogeneous studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The interventions implemented in the studies in this review led to
the identification ofmedication-related problems, confirming that
suboptimal prescribing is prevalent in this context. The majority
of medication-related problems were resolved through the inter-
ventions employed. In addition, evidence from two studies sug-
gested that the appropriateness of medication could be improved
through multifaceted interventions involving medication review
by pharmacists, transfer of information and multidisciplinary case
conferencing. Despite the identification and resolution of medi-
cation-related problems, and improvements in medication appro-
priateness, there is a lack of evidence on how this translates to
improvements in resident-related outcomes, namely adverse drug
events, hospital admissions, mortality and quality of life. The ef-
fect of interventions onmedicine costs was unclear, with two stud-
ies showing a reduction in costs and two studies showing no dif-
ference.
Implications for research
High-quality, adequately powered RCTs, ideally using cluster de-
signs, need to be conducted to identify effective interventions to
optimise prescribing for older care home residents. More studies
are needed to investigate the effectiveness of clinical decision sup-
port systems as well as multidisciplinary interventions in this con-
text. Further work is required to develop consensus on identifying,
defining, measuring, reporting and analysing important resident-
related outcomes, including quality of life. This will enable meta-
analyses to be conducted on future RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Claesson 1998
Methods Cluster-RCT (randomised by nursing home)
Total study duration: 14 months
Participants 1854 residents
33 nursing homes
Setting: nursing homes
Age: Average 83 years
Gender: Intervention 70% female; control 67% female
Country: Sweden
Date of study: 1994/95
Interventions The aim of the regular multidisciplinary meetings was to discuss and improve the use
of drugs in nursing homes, and to decrease the use of drugs which, according to the
advice of the workshop arranged by the Swedish Medical Products Agency, could cause
confusion and impaired memory. In group discussions, the physician, pharmacist, one
or more of the nursing home nurses, and in many cases, one or more of the assistant
nurses and nurse aides reviewed the drug use of all residents on a monthly basis over
a period of one year. The length and frequency of the meetings were adjusted by the
participants to local conditions. The therapy changes that were discussed were thus based
on the physician’s medical knowledge, the pharmacist’s pharmaceutical knowledge, and
the nurses’ and other staff ’s knowledge about the patients’ social and functional status.
The selected pharmacists were educated prior to and during the intervention period. This
education took the form of lectures and workshops, which took place on five occasions,
twice before the intervention started and three times during the intervention period, for
a total of 65.5 hours. The lectures were given by recognised experts, including clinical
pharmacists, geriatricians, gerontologists, nurses and two community pharmacists with
experience in nursing home consulting. Topics covered were gerontology/geriatrics (12.
5 hours), drug use in the elderly (23.5 hours) and basic training in collaborative methods
(18.5 hours). In addition, the pharmacists worked with patient cases in small groups,
covering all the areas mentioned above (11 hours). In addition to the formal education,
the pharmacists formed regional networks. The networking took place locally, whenever
the pharmacist felt a need to have it. In order to make the networks constructive, the
whole group was instructed by an educational specialist on one occasion
Outcomes Medication-related problems
Not used for this review:
Drug use
Notes Supported by the National Corporation of Swedish Pharmacies and the Swedish Phar-
maceutical Society
Risk of bias
Bias Authors’ judgement Support for judgement
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Claesson 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Homes were matched in pairs then each
randomised to control or intervention. [At-
tempted to contact author for further in-
formation but unsuccessful]
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No objective outcomes
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Medication-related problems described for
residents receiving intervention
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk Medication-related problemsnotmeasured
at baseline
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Drug use
Adequate protection against contamina-
tion
Unclear risk Cluster design. [Attempted to contact au-
thor for further information but unsuccess-
ful]
Other bias Low risk Appears to be free of other sources of bias
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Crotty 2004a
Methods Cluster-RCT (randomised by care facility)
Total study duration: 3 months
Participants 10 facilities (5 intervention, 5 control). 154 residents (50 intervention, 54 control, 50
within-facility control)
Setting: High-level residential aged-care facilities (nursing homes)
Age: Intervention mean 85.3, control mean 83.6, within-facility control mean 84.6
Gender: Intervention male 22 (44%), control male 23 (43%), within-facility control
male 17 (34%)
Country: Australia
Date of Study: 1999 [Author contacted]
Interventions Outreach geriatric medication advisory service, case conferencing and medication review
GPs were invited to attend two multidisciplinary case conferences conducted 6-12 weeks
apart. The resident’s GP, a geriatrician, a pharmacist, residential care staff and a represen-
tative of the Alzheimer’s Association of South Australia attended the case conferences,
which were held at the facility. Residential care staff expanded on any issues in the case
notes that required discussion and the Alzheimer’s Association of South Australia rep-
resentative discussed non-pharmacological management of dementia-related behaviour.
Each case conference was chaired by the GP, who used their medical records in addition
to case notes from the facility. A problem list was developed by the GP in conjunction
with the care staff and a medication review was conducted prior to each case conference.
All facilities in the study, including those in the control group, received a half-day work-
shop provided by the Alzheimer’s Association of South Australia, which examined the
use of a toolkit in the management of challenging behaviours
Outcomes Measured at baseline and three months post-intervention:
Medication appropriateness (MAI)
Drug costs (based on Australian Government Pharmaceutical Benefits Scheme)
Not used in this review:
Nursing Home Behaviour Problem Scale (NHBPS)
Number of drugs
Notes Funded by The Quality Use of Medicines Evaluation Programme 2000-2001, Health
and AgedCare, General Practice National Innovations Funding Pool 1999-2000, Health
and Aged Care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
used
Allocation concealment (selection bias) Low risk A researcher independent to the investiga-
tors generated the random sequence and
cluster design. Staff were asked to “nomi-
nate” 20 residents from intervention sites
and 10 residents from control sites. From
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Crotty 2004a (Continued)
the 20 intervention,10 were randomised
to intervention and ten to within-facility
control using sequential sealed opaque en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Assessed by independent pharmacist
blinded to allocation [author contacted]
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Reasons for attrition reported (all due to
deaths) and no statistically significant dif-
ference found in the proportionof residents
lost between groups. Described as inten-
tion-to-treat analysis by authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements High risk There were differences in the Medication
Appropriateness Index between groups at
baseline: Control 4.1 (95% CI 2.4-5.7);
Within-facility control 6.0 (95% CI 3.1-9.
0); Intervention 7.4 (95% CI 4.5-10.3)
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Medication Appropriateness Index
Adequate protection against contamina-
tion
Low risk Cluster design. Randomised by care facil-
ity. GPs were checked to avoid contamina-
tion between intervention and control res-
idents [author contacted]. No significant
differences found between the within-facil-
ity control and the control groups, there-
fore no evidence of a carry-over effect of the
intervention
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Crotty 2004a (Continued)
Other bias Low risk Appears to be free of other sources of bias
Crotty 2004b
Methods RCT (randomised by patient)
Total study duration: 8 weeks
Participants 110 patients (56 intervention, 54 control) from three hospitals discharged to 85 long-
term facilities
Setting: Long-term care facilities
Age: Mean 82.7, s.d. 6.4
Gender: 67 women (60.9%), 43 men (39.1%)
Country: Australia
Date of study: October 2002 to July 2003
Interventions Pharmacist transition coordinator.
The intervention focused on transferring information on medications to care providers
in the long-term care facilities, including the nursing staff, the family physician and the
accredited community pharmacist. On the patient’s discharge from the hospital to the
long-term care facility both the family physician and the community pharmacist were
faxed a medication transfer summary compiled by the transition pharmacist and signed
by the hospital medical officer. This communication supplemented the usual hospital
discharge summary and included specific information on changes to medications that
had been made in the hospital and aspects of medication management that required
monitoring
After transfer of the patient to the long-term care facility, the transition pharmacist co-
ordinated an evidence-based medication review that was to be performed by the com-
munity pharmacist contracted to the facility within 10 to 14 days of the transfer. The
transition pharmacist also coordinated a case conference involving him or herself, the
family physician, the community pharmacist and a registered nurse at the facility within
14 to 28 days of the transfer. At this case conference, the transition pharmacist provided
information concerning medication use and appropriateness
The usual hospital discharge process received by the control group included a standard
hospital discharge summary.
Outcomes Measured at baseline and eight weeks post-discharge:
Adverse drug events (not defined)
Hospital admissions (emergency department visits and hospital readmissions)
Medication-related problems
Medication appropriateness (MAI)
Not used for this review:
Falls
Worsening mobility
Worsening behaviours
Increased confusion
Worsening pain
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Crotty 2004b (Continued)
Notes Funded by the Australian Commonwealth Department Of Health and Ageing National
Demonstration Hospitals Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study biostatician provided a computer-
generated allocation sequence using block
randomisation
Allocation concealment (selection bias) Low risk Randomisation was coordinated by a cen-
tralised hospital pharmacy service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Independent pharmacists blinded to alloca-
tion assessed Medication Appropriateness
Index (MAI)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar Medication Appropriateness Index
scores at baseline. Other outcomes not
measured at baseline
Similar baseline characteristics Low risk Similar baseline characteristics reported ex-
cept more pre-admission medications dis-
continued during hospitalisation in the
control group
Reliable primary outcome measure Low risk Medication Appropriateness Index
26Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Crotty 2004b (Continued)
Adequate protection against contamina-
tion
High risk Randomised by patient therefore contami-
nation possible
Other bias Low risk Appears to be free of other sources of bias
Furniss 2000
Methods Cluster-RCT (randomised by care home)
Total study duration: 8 months
Participants 330 residents (172 control, 158 intervention); 14 homes (7 matched pairs)
Setting: Nursing homes
Age: Control mean 78.9 sd 13.7; intervention mean 83.5 sd 9.2
Gender: Control 115 (67%) females; intervention 125 (79%) females
Country: UK
Date of study: Not stated
Interventions Medication review by pharmacist
Medication review by the study pharmacist in the GP’s surgery, at the nursing home or
(in exceptional circumstances) over the telephone. The pharmacist collected details of
current medication for each resident from the medicines administration record chart in
the home, together with a brief medical history and any current problems identified by
the home staff. Three weeks after the medication review, the homes were revisited, to
ascertainwhether there hadbeen any immediate problemswith the changes inmedication
and to see if the suggested changes have been implemented
Outcomes Measured at time 0 (beginning of study), time 1at four months (beginning of interven-
tion) and at time 2 at eight months (end of intervention):
Hospital admissions (“inpatient days”)
Mortality
Medication-related problems (number of pharmacist recommendations,
acceptance of recommendations by the GP, number of treatment changes)
Medication costs (not defined, £ sterling)
Not used for this review:
Mini-Mental State Examination (MMSE)
Geriatric Depression Scale (GDS)
Brief Assessment Schedule Depression Cards (BASDEC)
Crichton-Royal Behaviour Rating Scale (CRBRS)
Number of drugs per resident
Type of drugs
Reason for neuroleptic use
Use of primary and secondary care resources
Number of accidents
Falls
Notes Funded by the North West NHS Executive
Risk of bias
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Furniss 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated pseudo random
numbers used
Allocation concealment (selection bias) Low risk Homes were randomised at the start of the
start of a four-month observation phase.
Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding described
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements High risk 14 (8.1%) deaths in control group versus
22 (13.9%) deaths in intervention group
at baseline. No baseline measurements of
other primary outcomes of this review
Similar baseline characteristics High risk Slightly fewer residents in the interven-
tion group (158) versus control (172). In
the control group, residents were younger
(mean 78.9 s.d. 13.7 versus mean 83.5 s.
d. 9.2) and there were fewer females (67%
versus 79%)
Reliable primary outcome measure Low risk Crichton-Royal Behaviour Rating Scale
Adequate protection against contamina-
tion
Low risk Randomised by care home (which were in
different geographical areas)
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Furniss 2000 (Continued)
Other bias Low risk Appears to be free of other sources of bias
Gurwitz 2008
Methods Cluster-RCT (randomised by care unit within two long-term care facilities)
Total study duration: 12 months
Participants 1,118 resident in 29 units in two long-term care facilities
Setting: Long-term care facilities
Age: Average 87.2 years
Gender: 71.3% female
Country: US and Canada
Date of study: 2006-7 [Author contacted]
Interventions Computerised provider order entry with clinical decision support
A team of geriatricians, pharmacists, health services researchers and information system
specialists designed the clinical decision support system
The team reviewed the types of preventable adverse drug events based on previous
research and widely accepted published criteria for suboptimal prescribing in elderly
people available at the time of this study. All serious drug-drug interactions from a
standard pharmaceutical drug interaction database were also reviewed and alerts were
included for a limited number of more than 600 potentially serious interactions that
were reviewed. For residents on the intervention units, the alerts were displayed in a pop-
up box to prescribers in real time when a drug order was entered. The pop-up boxes
were informational; they did not require specific actions from the prescriber and did not
produce or revise orders automatically. On the control units, the alerts were not displayed
to the prescribers
Outcomes Measured throughout study period (resident-months):
Adverse drug event (“an injury resulting from the use of a drug” includes medication
error and adverse drug reaction)
Severity of adverse drug event
Preventability of adverse drug event
Notes Supported by the Agency for Healthcare Research and Quality.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used. Within each
block, units were randomly assigned using
the random function in Microsoft Excel®.
[Author contacted]
Allocation concealment (selection bias) Low risk Cluster design
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Gurwitz 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Outcome assessors were blind to allocation
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No objective outcomes
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Not measured in this study
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk No baseline measurements of adverse drug
effects
Similar baseline characteristics Unclear risk Baseline characteristics not reported, how-
ever, units were matched for bed size and
general characteristics of residents and the
unit
Reliable primary outcome measure Low risk Number of adverse drug events
Adequate protection against contamina-
tion
High risk Cluster design. Efforts were made to limit
crossover of prescribers between interven-
tion and control units, however, some pre-
scribers worked simultaneously on both in-
tervention and control units. In an effort
to assess the possibility that this may have
led to changes in behaviour in the con-
trol group, the rate of responses to “unseen”
alerts in the control units during the first
versus the last quarter of the study was as-
sessed at one of the study sites. The rate of
response was lower in the last quarter, sug-
gesting that prescribers did not adopt new
habits due to seeing alerts on intervention
units
Other bias Low risk Appears to be free of other sources of bias
30Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roberts 2001
Methods Cluster-RCT (randomised by care home)
Total study duration: Two years
Participants 3230 residents (905 intervention, 13 homes); 2325 control, 39 homes)
Setting: Nursing homes
Age:
Intervention <60 2.0%, 60-69 6.6%, 70-79 21.9%, 80-89 47.4%, 90-99 20.7%, ≥
100 1.7%
Control <60 2.6%, 60-69 5.4%, 70-79 22.3%, 80-89 46.7%, 90-99 21.1%, ≥ 100 1.
6%
Gender: Not reported
Country: Australia
Date of Study: Not reported
Interventions Three phase intervention: introducing a new professional role to stakeholders with rela-
tionship building; nurse education; and medication
review by pharmacists.
The clinical pharmacy service model introduced to each nursing home was supported
with activities such as focus groups facilitated by a research nurse, written and telephone
communication, and face-to-face professional contact between nursing home staff and
clinical pharmacists on issues such as drug policy and specific resident problems, together
with education andmedication review by pharmacists holding a postgraduate diploma in
clinical pharmacy. This was amultifaceted intervention directly targeting nursing homes.
Most of the contact with GPs was indirect, using the existing relationships between nurs-
ing homes and visiting GPs. A number of focus groups and personal interviews about
the project were conducted with GPs. In intervention homes, problem-based education
sessions (6±9 seminars totalling approximately 11 h per home) were provided to nurses.
Sessions addressed basic geriatric pharmacology and some common problems in long-
term care (depression, delirium and dementia, incontinence, falls, sleep disorders, con-
stipation and pain). Sessions were supported by wall charts, bulletins, telephone calls and
clinical pharmacy visits, averaging 26 h contact per home over the study. Written, refer-
enced drug regimen reviews were prepared by the clinical pharmacists for 500 individual
residents selected by the nursing home staff. The reviews highlighted the potential for:
(1) adverse drug effects, (2) ceasing one or more drugs, (3) adding drugs, (4) better use of
specific drug therapy, particularly psychoactive drugs, (5) nondrug interventions, and (6)
adverse effect and drug response monitoring. Initial reports (61% of total) were audited
by a geriatrician before dissemination. Reports were placed in each resident’s nursing
home records, made available to the resident’s GP and discussed with nursing staff. Drugs
commonly targeted in reviews and education sessions included laxatives, histamine H2-
receptor antagonists, allopurinol, quinine, antibacterials, paracetamol, nonsteroidal anti-
inflammatory drugs (NSAIDs) and psychoactive drugs
Outcomes Measured at baseline and 12 months post-intervention:
Hospital admissions (not defined)
Mortality (survival also assessed at 22 months)
Medication-related problems
Medication costs (per resident per year based on prescription claims data)
Not used for this review:
Adverse events (from incident reports)
Resident Classification Instrument (RCI)
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Roberts 2001 (Continued)
Drug use
Notes Supported by the Commonwealth Government of Australia under the Pharmaceutical
Education Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Homes were assigned to intervention or
control by being “drawn from a hat”
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk No blinding reported, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Slight imbalance in mortality and hospi-
talisations at baseline; however this was ac-
counted for in the analysis
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Mortality and Resident Classification In-
strument (RCI)
Adequate protection against contamina-
tion
Unclear risk Cluster design. [Attempted to contact au-
thor for further information but no re-
sponse]
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Roberts 2001 (Continued)
Other bias High risk Medication reviews were undertaken for a
non-random subsample of 500 residents
(total intervention residents 905) selected
by nursing staff
Strikwerda 1994
Methods RCT (randomised by GP)
Total study duration: 6 weeks
Participants 196 residents
One nursing home
Age: mean 84.5 years (59-100)
Gender: 25% male
Country: Netherlands
Date of study: 1993
Interventions Feedback on GP prescribing from community pharmacist
Group A received usual care, group B GPs issued with a medication list used by their
patients, group C GPs received a medication list plus feedback from community phar-
macist
Outcomes Medication-related problems
Not used for this review: drug use
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Not measured in this study
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Strikwerda 1994 (Continued)
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk No baseline measurements of medication-
related problems
Similar baseline characteristics High risk Most baseline characteristics similar, how-
ever fewer males in group A and fewer
medicines per resident in group B
Reliable primary outcome measure Low risk Drug use
Adequate protection against contamina-
tion
High risk Randomised by GP, however control and
intervention residents resided in the same
nursing home
Other bias Low risk Appears to be free of other sources of bias
Zermansky 2006
Methods RCT (randomised by patient)
Total study duration: 6 months
Participants 661 (331 intervention, 330 control) care home residents, 65 care homes
Setting: Nursing and residential homes for older people
Age: Intervention mean 85.3 (IQR 81-90); control mean 84.9 (IQR 80-90)
Gender: Intervention 75 (22.7%) male; control 79 (23.9%) male
Country: UK
Date of study: 2002
Interventions Medication review by a single pharmacist.
A clinical medication reviewwas conducted by the study pharmacist who held a postgrad-
uate qualification in clinical pharmacy within 28 days of randomisation. It comprised
a review of the GP clinical record and a consultation with the resident and carer. The
pharmacist formulated recommendations with the resident and carer and passed them
on a written proforma to the GP for acceptance and implementation. GP acceptance
was signified by ticking a box on the proforma. Control patients received usual GP care
Outcomes Measured at baseline and six months ± three weeks post-randomisation:
Hospital admissions (non-elective)
Mortality
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Zermansky 2006 (Continued)
Medication-related problems
Medicine costs (cost of 28 days of repeat medicines per participant)
Not used for this review:
Number of changes in medicines per participant
Number of medicines per participant
Recorded medication reviews
Falls
SMMSE
Barthel index
Number of GP consultations
Notes Funded by The Health Foundation, 90 Long Acre, London WC2 9RA (Registered
Charity Number 286967)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised in randomly
sized blocks of 2 to 8 patients using an algo-
rithm written in Visual Basic in Microsoft
Access
Allocation concealment (selection bias) Low risk Not reported in paper. Allocation was con-
cealed to the research pharmacist and nurse
data collector by statistician [Author con-
tacted]
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open design, no blinding attempted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
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Zermansky 2006 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar baseline measurements for hospital
admissions and medicine costs
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Number of changes in medication
Adequate protection against contamina-
tion
High risk Randomised by patient therefore contami-
nation possible
Other bias Unclear risk Sample size calculation indicated that 1600
residents were required, however, only 661
residents were recruited
Characteristics of ongoing studies [ordered by study ID]
Desborough
Trial name or title Multi-professional clinical medication reviews in care homes for the elderly: study protocol for a randomised
controlled trial with cost effectiveness analysis
Methods Cluster RCT (randomised by care home)
Total Study Duration: 12 months
Participants Residents of 30 care homes for older people (average age >65)
Interventions Intervention homes will receive a multi-professional medication review at baseline and at 6 months, with
follow-up at 12 months. Control homes will receive usual care (support they currently receive from the
National Health Service), with data collection at baseline and 12 months
Outcomes Emergency hospital admissions and Accident and Emergency (A&E) visits (number of admissions in six
months per patient)
Mortality
Potentially inappropriate prescribing (number of drugs whichmatch the STOPPcriteria at each data collection
point)
Medication costs (mean drug costs per patient - net ingredient costs for 28 days)
Not used for this review:
Number of falls (mean per patient per month)
Utilisation of primary care, secondary care and personal social services health professional time (GP, nurse
and other)
Starting date 2011
Contact information
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Desborough (Continued)
Notes
37Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study,Country, Design Participants Intervention Outcome measures Duration
Claesson 1998
Sweden
Cluster-RCT
1854 residents in 33
nursing homes
Multidisciplinary
meetings with physician,
pharmacist and nurse(s)
Medication-related
problems
14 months
Crotty 2004a
Australia
Cluster-RCT
154 residents in 10 nurs-
ing homes
Multidisciplinary case
conferencing with GP, a
geriatrician, a pharma-
cist, residential care staff
and an Alzheimer’s Asso-
ciation representative
Medication
Appropriateness Index
3 months
Crotty 2004b
Australia
Patient-RCT
110 patients discharged
to 85 long-term care fa-
cilities
Pharmacist
transition co-ordinator.
Transfer of medicines
information to nursing
staff, family physician
and community phar-
macist plus medication
review and case confer-
encing
Adverse drug events
Hospital admissions
Medication-related
problems
Medication
Appropriateness Index
8 weeks
Furniss 2000
UK
Cluster-RCT
330 residents in 14 nurs-
ing homes
Medication review by a
single pharmacist
Hospital admissions
Mortality
Medication-related
problems
Medicine costs
8 months
Gurwitz 2008
USA/Canada
Cluster-RCT
1118 residents in 29
units in 2 long-term care
facilities
Computerised provider
order entry with clinical
decision support
Adverse drug events 12 months
Roberts 2001
Australia
Cluster-RCT
3230 residents in 52
nursing homes
Introductionof newpro-
fessional role, nurse ed-
ucation and medication
review by pharmacists
Hospital admissions
Mortality
Medication-related
problems
Medicine costs
24 months
Strikwerda 1994
Netherlands
Cluster-RCT
196 residents in 1 nurs-
ing home
Feedback on GP pre-
scribing from commu-
nity pharmacist
Medication-related
problems
6 weeks
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Table 1. Summary of study characteristics (Continued)
Zermansky 2006
UK
Patient-RCT
661 residents in 65 care
homes
Medication review by a
single pharmacist
Hospital admissions
Mortality
Medication-related
problems
Medicine costs
6 months
A P P E N D I C E S
Appendix 1. Electronic database search strategies
Cochrane Database of Systematic Reviews Issue 11, 2012, Wiley
Search run 16th November 2012
Number of results: 6
#1 MeSH descriptor Polypharmacy, this term only (71)
#2 (polypharm*):ti,ab,kw (158)
#3 (multi-drug* or multidrug*) NEAR/2 (therapy or therapies or prescribing or treatment or regime*):ti,ab,kw (263)
#4 (beer NEAR/2 criter*):ti,ab,kw (9)
#5 (appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or
multiple or concurrent*) NEAR/2 (medicine* or medication* or prescription* or drug*):ti,ab,kw (1415)
#6 (over NEAR/1 prescript*) or (overprescrib* or overprescript*):ti,ab,kw (29)
#7 (under NEAR/1 prescript*) or (underprescrib* or underprescript*):ti,ab,kw (6)
#8 “medication appropriateness index”:ti,ab,kw (15)
#9 (quality NEAR/1 (prescribing or prescription* or medication*)):ti,ab,kw (30)
#10 (improv* NEAR/1 (prescrib* or prescription* or pharmaco*)):ti,ab,kw (147)
#11 “case conferencing”:ti,ab,kw (9)
#12 MeSH descriptor Medication Therapy Management, this term only (18)
#13 “medication* management”:ti,ab,kw or “medication* therapy management”:ti,ab,kw or “medication* strategy”:ti,ab,kw or
“medication* strategies”:ti,ab,kw or (medication* NEAR/2 review*):ti,ab,kw (408)
#14 “drug regimen review*”:ti,ab,kw or (drug NEAR/1 utili?ation NEAR/2 (review* or evaluat*)):ti,ab,kw (126)
#15 MeSH descriptor Drug Utilization Review, this term only (102)
#16 “drug related problem*”:ti,ab,kw or (prescription* NEAR/2 pattern*):ti,ab,kw or “Assessing care of vulnerable elders”:ti,ab,kw
or (acove):ti,ab,kw or (stopp):ti,ab,kw (122)
#17 “start screening tool”:ti,ab,kw or “Screening Tool of Older Person’s Prescriptions”:ti,ab,kw or “Screening Tool to Alert doctors
to Right Treatment”:ti,ab,kw (0)
#18 MeSH descriptor Medication Errors, this term only (163)
#19 (pharmaceutical* or pharmacist* or prescrib*):ti,ab,kw (11159)
#20 MeSH descriptor Pharmaceutical Preparations, this term only (225)
#21 MeSH descriptor Pharmacists, this term only (325)
#22 MeSH descriptor Pharmacists’ Aides, this term only (5)
#23 MeSH descriptor Prescription Drugs, this term only (45)
#24 MeSH descriptor Drug Prescriptions, this term only (402)
#25 MeSH descriptor Pharmaceutical Services, this term only (93)
#26 MeSH descriptor Drug Toxicity, this term only (359)
#27 (pharmacotherap*):ti,ab,kw (6758)
#28 MeSH descriptor Drug Therapy, this term only (425)
39Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#29 MeSH descriptor Drug Monitoring, this term only (907)
#30 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29) (21231)
#31 MeSH descriptor Homes for the Aged, this term only
#32 “home* for the aged”:ti,ab,kw or (aged NEAR/2 (care or nursing or healthcare or residential) NEAR/2 (facility or facilities or
home*)):ti,ab,kw or (geriatric or elderly) NEAR/2 (facility or facilities or care home*):ti,ab,kw
#33 MeSH descriptor Nursing Homes explode all trees (401)
#34 MeSH descriptor Hospitals, Veterans, this term only (274)
#35 (#31 OR #32 OR #33 OR #34) (1525)
#36 (care or convalescent) NEXT (home or homes or center* or centre* or facility or facilities):ti,ab,kw (2086)
#37 (skilled or intermediate) NEXT (nursing facility or nursing facilities):ti,ab,kw (0)
#38 (resident* NEAR/2 (care or facility or facilities)):ti,ab,kw (466)
#39 (nursing or group or residential) NEXT (home or homes):ti,ab,kw (1763)
#40 (longterm or long term) NEAR/3 (care or facility or facilities):ti,ab,kw (1904)
#41 MeSH descriptor Long-Term Care, this term only (963)
#42 MeSH descriptor Residential Facilities, this term only (116)
#43 (assisted living):ti,ab,kw (437)
#44 MeSH descriptor Halfway Houses, this term only (17)
#45 (#36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44) (5838)
#46 MeSH descriptor Aged explode all trees (499)
#47 MeSH descriptor Geriatrics, this term only (175)
#48 (gerontol* or ageing or aging or elder* or geriatric* or seniors or old age or older or late* life):ti,ab,kw (310000)
#49 (older NEXT (person* or people or adult* or patient* or inpatient* or outpatient*)):ti,ab,kw (5427)
#50 MeSH descriptor Veterans explode all trees (379)
#51 (veteran*):ti,ab,kw (1874)
#52 (#46 OR #47 OR #48 OR #49 OR #50 OR #51) (310561)
#53 (#45 AND #52) (4152)
#54 (#30 AND ( #35 OR #53 )) (6)
Cochrane Central Register of Controlled Trials (CENTRAL) Issue 11, 2012, Wiley
Search run 16th November 2012
Number of results: 281
#1 MeSH descriptor Polypharmacy, this term only (71)
#2 (polypharm*):ti,ab,kw (158)
#3 (multi-drug* or multidrug*) NEAR/2 (therapy or therapies or prescribing or treatment or regime*):ti,ab,kw (263)
#4 (beer NEAR/2 criter*):ti,ab,kw (9)
#5 (appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or
multiple or concurrent*) NEAR/2 (medicine* or medication* or prescription* or drug*):ti,ab,kw (1415)
#6 (over NEAR/1 prescript*) or (overprescrib* or overprescript*):ti,ab,kw (29)
#7 (under NEAR/1 prescript*) or (underprescrib* or underprescript*):ti,ab,kw (6)
#8 “medication appropriateness index”:ti,ab,kw (15)
#9 (quality NEAR/1 (prescribing or prescription* or medication*)):ti,ab,kw (30)
#10 (improv* NEAR/1 (prescrib* or prescription* or pharmaco*)):ti,ab,kw (147)
#11 “case conferencing”:ti,ab,kw (9)
#12 MeSH descriptor Medication Therapy Management, this term only (18)
#13 “medication* management”:ti,ab,kw or “medication* therapy management”:ti,ab,kw or “medication* strategy”:ti,ab,kw or
“medication* strategies”:ti,ab,kw or (medication* NEAR/2 review*):ti,ab,kw (408)
#14 “drug regimen review*”:ti,ab,kw or (drug NEAR/1 utili?ation NEAR/2 (review* or evaluat*)):ti,ab,kw (126)
#15 MeSH descriptor Drug Utilization Review, this term only (102)
#16 “drug related problem*”:ti,ab,kw or (prescription* NEAR/2 pattern*):ti,ab,kw or “Assessing care of vulnerable elders”:ti,ab,kw
or (acove):ti,ab,kw or (stopp):ti,ab,kw (122)
#17 “start screening tool”:ti,ab,kw or “Screening Tool of Older Person’s Prescriptions”:ti,ab,kw or “Screening Tool to Alert doctors
to Right Treatment”:ti,ab,kw (0)
40Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#18 MeSH descriptor Medication Errors, this term only (163)
#19 (pharmaceutical* or pharmacist* or prescrib*):ti,ab,kw (11159)
#20 MeSH descriptor Pharmaceutical Preparations, this term only (225)
#21 MeSH descriptor Pharmacists, this term only (325)
#22 MeSH descriptor Pharmacists’ Aides, this term only (5)
#23 MeSH descriptor Prescription Drugs, this term only (45)
#24 MeSH descriptor Drug Prescriptions, this term only (402)
#25 MeSH descriptor Pharmaceutical Services, this term only (93)
#26 MeSH descriptor Drug Toxicity, this term only (359)
#27 (pharmacotherap*):ti,ab,kw (6758)
#28 MeSH descriptor Drug Therapy, this term only (425)
#29 MeSH descriptor Drug Monitoring, this term only (907)
#30 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29) (21231)
#31 MeSH descriptor Homes for the Aged, this term only
#32 “home* for the aged”:ti,ab,kw or (aged NEAR/2 (care or nursing or healthcare or residential) NEAR/2 (facility or facilities or
home*)):ti,ab,kw or (geriatric or elderly) NEAR/2 (facility or facilities or care home*):ti,ab,kw
#33 MeSH descriptor Nursing Homes explode all trees (401)
#34 MeSH descriptor Hospitals, Veterans, this term only (274)
#35 (#31 OR #32 OR #33 OR #34) (1525)
#36 (care or convalescent) NEXT (home or homes or center* or centre* or facility or facilities):ti,ab,kw (2086)
#37 (skilled or intermediate) NEXT (nursing facility or nursing facilities):ti,ab,kw (0)
#38 (resident* NEAR/2 (care or facility or facilities)):ti,ab,kw (466)
#39 (nursing or group or residential) NEXT (home or homes):ti,ab,kw (1763)
#40 (longterm or long term) NEAR/3 (care or facility or facilities):ti,ab,kw (1904)
#41 MeSH descriptor Long-Term Care, this term only (963)
#42 MeSH descriptor Residential Facilities, this term only (116)
#43 (assisted living):ti,ab,kw (437)
#44 MeSH descriptor Halfway Houses, this term only (17)
#45 (#36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44) (5838)
#46 MeSH descriptor Aged explode all trees (499)
#47 MeSH descriptor Geriatrics, this term only (175)
#48 (gerontol* or ageing or aging or elder* or geriatric* or seniors or old age or older or late* life):ti,ab,kw (310000)
#49 (older NEXT (person* or people or adult* or patient* or inpatient* or outpatient*)):ti,ab,kw (5427)
#50 MeSH descriptor Veterans explode all trees (379)
#51 (veteran*):ti,ab,kw (1874)
#52 (#46 OR #47 OR #48 OR #49 OR #50 OR #51) (310561)
#53 (#45 AND #52) (4152)
#54 (#30 AND ( #35 OR #53 )) (281)
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-maximizing version
(2008 revision); Ovid format
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized.ab.
4 placebo.ab.
5 drug therapy.fs.
6 randomly.ab.
7 trial.ab.
8 groups.ab.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 exp animals/ not humans.sh.
11 9 not 10
MEDLINE, 1980-, OvidSP
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Search run 16th November 2012 [database last updated November, week 2, 2012]
Number of results: 1381
1 polypharmacy/ (1998)
2 polypharm*.ti,ab. (2606)
3 ((multi-drug* or multidrug*) adj2 (therapy or therapies or prescribing or treatment or regime*).ti,ab. (2285)
4 (beer* adj1 criter*).ti,ab. (187)
5 ((appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or
multiple or concurrent*) adj2 (medicine? or medication? or prescription* or drug*)).ti,ab. (16485)
6 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,ab. (542)
7 ((under adj prescript*) or (underprescrib* or underprescript*)).ti,ab. (215)
8 medication appropriateness index.ti,ab. (52)
9 (quality adj (prescribing or prescription? or medication?)).ti,ab. (70)
10 (improv* adj (prescrib* or prescription? or pharmaco*)).ti,ab. (1512)
11 case conferencing.ti,ab. (40)
12 medication therapy management/ (445)
13 (medication? management or medication? therapy management or medication? strategy or medication? strategies or (medication?
adj2 review*)).ti,ab. (2391)
14 drug regimen review*.ti,ab. (52)
15 drug utilization review/ (2780)
16 (drug adj utili?ation adj2 (review* or evaluat*)).ti,ab. (348)
17 drug related problem?.ti,ab. (702)
18 ((prescribing or prescription?) adj2 pattern?).ti,ab. (2205)
19 Assessing care of vulnerable elders.ti,ab. (43)
20 acove.ti,ab. (30)
21 stopp.ti,ab. (43)
22 start screening tool.ti,ab. (10)
23 Screening Tool of Older Person’s Prescriptions.ti,ab. (11)
24 Screening Tool to Alert doctors to Right Treatment.ti,ab. (9)
25 Medication Errors/ (9580)
26 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. (142522)
27 pharmaceutical preparations/ (45187)
28 Pharmacists/ (9723)
29 Pharmacists’ Aides/ (489)
30 Prescription Drugs/ (2261)
31 Drug Prescriptions/ (20951)
32 Pharmaceutical Services/ (3895)
33 drug toxicity/ (5710)
34 pharmacotherap*.ti,ab. (18959)
35 drug therapy/ (33168)
36 drug monitoring/ (12728)
37 or/1-36 [Prescribing/medication terms] (279642)
38 Homes for the Aged/ or “homes for the aged”.tw. (10633)
39 exp Nursing Homes/ or nursing home?.tw. (30522)
40 (aged adj2 (care or nursing or healthcare or residential) adj2 (facility or facilities or home?)).ti,ab. (268)
41 ((geriatric or elderly) adj2 (facility or facilities or care home?)).ti,ab. (296)
42 Hospitals, Veterans/ (5454)
43 or/38-42 [Care facilities- aged terms] (40335)
44 ((care or convalescent) adj (home? or center? or centre? or facility or facilities)).ti,ab. (26613)
45 ((skilled or intermediate) adj (nursing facility or nursing facilities)).ti,ab. (1272)
46 (resident* adj2 (care or facility or facilities)).ti,ab. (4925)
47 ((nursing or group or residential) adj home?).ti,ab. (20829)
48 Long-Term Care/ (20740)
49 ((longterm or long term) adj3 (care or facility or facilities)).ti,ab. (14906)
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50 (healthcare adj2 (facility or facilities)).ti,ab. (1717)
51 Residential Facilities/ (4463)
52 Assisted Living Facilities/ (772)
53 assisted living.ti,ab. (1104)
54 Halfway houses/ (1011)
55 or/44-54 [Other residential care terms] (78047)
56 exp aged/ (2179029)
57 Geriatrics/ (26019)
58 (gerontol* or ageing or aging or elder* or geriatric* or seniors or old age or older or late* life).ti,ab. (466530)
59 (older adj (person* or people or adult* or patient* or inpatient* or outpatient*)).ti,ab. (63257)
60 veterans/ (8246)
61 veteran*.ti,ab. (18509)
62 or/56-61[Elderly terms] (2404467)
63 randomized controlled trial.pt. (342057)
64 controlled clinical trial.pt. (85675)
65 random*.ti,ab. (586198)
66 drug therapy.fs. (1586933)
67 trial.ab. (253559)
68 groups.ab. (1144975)
69 or/63-68 (3059105)
70 exp animals/ not humans.sh. (3811050)
71 69 not 70 [RCT filter] (2598604)
72 37 [Prescribing/medication terms] and 43 [Care facilities- aged terms] (2126)
73 37 [Prescribing/medication terms] and 55 [Other residential care terms] (4013)
74 73 [Prescribing/medication terms and Other residential care terms] and 62 [Elderly terms] (2258)
75 (72 or 74) and 71 [RCT filter] (1399)
76 limit 75 to yr=“1980 -Current” (1381)
EMBASE, 1980- , OvidSP
Search run 16th November 2012 [Database last updated week 45, 2012]
Number of results: 3530
1 polypharmacy/ (5545)
2 polypharm*.ti,ab. (4282)
3 ((multi-drug* or multidrug*) adj2 (therapy or therapies or prescribing or treatment or regime*)).ti,ab. (3512)
4 (beer* adj1 criter*).ti,ab. (338)
5 ((appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive
or multiple or concurrent* or adverse) adj2 (medicine? or medication? or prescription* or prescrib* or drug*)).ti,ab. (46912)
6 ((over adj1 prescript*) or (over adj1 prescrib*) or (overprescrib* or overprescript*)).ti,ab. (1197)
7 ((under adj prescript*) or (under adj prescrib*) or (underprescrib* or underprescript*)).ti,ab. (488)
8 medication appropriateness index/ or medication appropriateness index.ti,ab. (74)
9 (quality adj (prescribing or prescription? or medication?)).ti,ab. (103)
10 (improv* adj (prescrib* or prescription? or pharmaco*)).ti,ab. (2123)
11 case conferencing.ti,ab. (53)
12 medication therapy management/ (1228)
13 (medication? management or medication? therapy management or drug therapy management or medication? strategy or
medication? strategies or (medication? adj2 review*)).ti,ab. (4178)
14 drug regimen review*.ti,ab. (84)
15 (drug adj utili?ation adj2 (review* or evaluat*)).ti,ab. (574)
16 drug utilization/ (15587)
17 ((drug or medication) adj related problem?).ti,ab. (1548)
18 ((prescribing or prescription?) adj2 pattern?).ti,ab. (3426)
19 Assessing care of vulnerable elders.ti,ab. (50)
20 Assessing care of vulnerable elders.mp. (50)
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21 “Assessing Care of Vulnerable Elders”/ (1)
22 acove.ti,ab. (46)
23 stopp.ti,ab. (130)
24 start screening tool.ti,ab. (22)
25 Screening Tool of Older Person’s Prescriptions.ti,ab. (25)
26 Screening Tool to Alert doctors to Right Treatment.ti,ab. (21)
27 medication error/ (11089)
28 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. (247238)
29 drug/ (40640)
30 pharmacist/ or pharmacy technician/ (41871)
31 prescription drug/ (2125)
32 prescription/ (98072)
33 pharmacy/ (47765)
34 pharmacotherap*.ti,ab. (30503)
35 exp drug therapy/ (1657001)
36 drug monitoring/ (38809)
37 drug toxicity/ (51048)
38 “drug use”/ (65381)
39 or/1-38 [Prescribing/medication terms] (2094786)
40 home for the aged/ or “home? for the aged”.ti,ab. (11978)
41 ((care or convalescent) adj (home? or center? or centre? or facility or facilities)).ti,ab. (36574)
42 public hospital/ (27380)
43 exp Nursing Homes/ (39622)
44 ((skilled or intermediate) adj (nursing facility or nursing facilities*)).ti,ab. (1585)
45 ((aged or geriatric or elderly) adj2 (care home? or facility or facilities or residential)).ti,ab. (1081)
46 or/40-45 [Care facilities -aged terms] (104001)
47 (resident* adj2 (care or facilit*)).ti,ab. (6504)
48 ((nursing or group or residential) adj home*).ti,ab. (27136)
49 long term care/ (83560)
50 ((longterm or long term) adj3 (care or facilit*)).ti,ab. (20505)
51 residential home/ (5457)
52 residential home*.ti,ab. (926)
53 assisted living facility/ (953)
54 assisted living.ti,ab. (1356)
55 (life care cent* or continued care cent* or extended care facilit*).ti,ab. (523)
56 halfway house/ (1240)
57 or/40-55 [Care facilities - general] (200251)
58 exp aged/ (2136072)
59 GERIATRICS/ (34537)
60 (aged or elder* or geriatric* or seniors or old age or older or late* life).ti,ab. (904844)
61 (old* adj (person* or people or adult* or patient* or inpatient* or outpatient*)).ti,ab. (127968)
62 veteran/ (8498)
63 veteran*.ti,ab. (23699)
64 or/58-63 [Elderly terms] (2696684)
65 57 and 64 (70919)
66 clinical trial/ (882811)
67 randomized controlled trial/ (335600)
68 randomization/ (60313)
69 single blind procedure/ (16719)
70 double blind procedure/ (116669)
71 Crossover procedure/ (35906)
72 randomi?ed controlled trial*.ti,ab. (81408)
73 RCT.tw. (10604)
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74 random allocation.ti,ab. (1267)
75 randomly allocated.ti,ab. (18323)
76 allocated randomly.ti,ab (1885)
77 (allocated adj2 random).ti,ab. (869)
78 single blind*.ti,ab. (13170)
79 double blind*.ti,ab. (142385)
80 ((treble or triple) adj2 blind*).ti,ab. (388)
81 prospective study/ (220972)
82 or/66-81 (1227757)
83 case study/ or case report.ti,ab. (287404)
84 abstract report/ or letter/ (870000)
85 or/83-84 (1153094)
86 82 not 85 [SIGN RCT filter minus placebo] (1196147)
87. 39 and (46 or 65) and 86 (3579)
88 limit 87 to yr=“1980 -Current (3530)
EPOC Group, Specialised Register, Reference Manager
Search run November 2012
Number of results: 565
1 All Non-Indexed {prescrib\*} OR {prescription\*} OR {medication\* use} OR {drug
therapy\*} OR {polypharmacy}
2 AND Title, primary {improv\*} OR {optimi\*} OR {rational} OR {irrational} OR {evidence\*}
3 OR Keywords [7] {prescrib*] AND {practice*}
4 OR Keywords [7] {prescrib*} AND {improv*}
5 OR Keywords [7] {prescrib*} AND {compliance*}
6 OR Abstract [25] {rational} AND {prescrib\*}
7 OR Abstract [25] {irrational} AND {prescrib\*}
8 OR Abstract [25] {improv\* prescrib\*} OR {optim\*prescrib\*} OR {rational prescrib\*}
OR {irrational prescrib\*} OR {reduc\*overprescrib\*}
9 OR Abstract [25] {reduc\*} AND {medication\*use\*}
10 OR Title, primary {improv\*} AND {medicine\*}
11 OR All Non-Indexed unnecessary prescrib\*
12 OR Abstract [25] {polypharmacy\*} AND {reduc\*}
13 OR Keywords [7] {prescrib*} AND {adher*}
14 OR Keywords [7] medication adherence*
OR ALL Non-Indexed fields : ACOVE or STARTT found one more citation; total 565 -
Ageline,1966-, EBSCO
Search run November 2012
Number of results: 186
S1 TI ( prescribing or polypharm* or pharmacist* ) or SU ( prescribing or polypharm* )
S2 TX (appropriat* w2 prescrib*) OR (inappropriat* w2 prescrib*) or (optim* w2 prescrib*) or (suboptim* w2 prescrib*) or (sub-
optim* w2 prescrib*) or (unnecessary n2 medicat*) or (unnecessary n2 prescrib*) or TX medication* w2 appropriat* or (appropriat*
w2 medicat*) OR (inappropriat* w2 medicat*) or (optim* w2 medicat*) or (suboptim* w2 medicat*) or (sub-optim* w2 medicat*) or
overprescrib* or overmedicat* or ”over-medicat*“
S3 TX ”Assessing care of vulnerable elders“ or TX ”Screening Tool of Older Person’s Prescriptions“ OR TX ”Screening Tool to
Alert doctors to Right Treatment“ OR TX ”start screening tool“ or ”beers criteria“ or ”beer’s criteria“
S4 TX overprescrib* or inappropriat* prescribe*
S5 DE ”Nursing Homes“ OR TX ”nursing home“ or TX ”nursing homes“
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S6 TX ( care w2 home* OR care w2 facility or care w2 facilities ) or TX ( ”homes for the aged“ or ”old age home*“ ) or TX
(”geriatric homes“)
S7 TX nursing w2 home*
S8 S5 or S6 or S7
S9 (drug w1 therap*) or (drug w2 utili*)
S10 SU (prescription or prescriptions or pharma* )
S11 DE ”Medication Errors“
S12 SU drug OR SU drugs or SU medication*
S13 TI medication error*
S14 (S9 or S10 or S11 or S12 or S13) AND S8
S15 (S1 or S2 or S3 or S4) and S8
S16 SU ( trial or trials ) or SU studies or TI ( study or trial ) or TX ( control w3 area or control w3 cohort* or control w3 compar*
or control w3 condition* or control w3 group* or control w3 intervention* or control w3 participant* or control* w3 study ) or TX (
random* OR controlled )
S17 (S14 OR S15) AND S16
CINAHL (Cumulative Index to Nursing and Allied Health Literature), 1980- , EBSCO
Search run 16th November 2012
Number of results: 407
S1 MH polypharmacy (1,327)
S2 TI polypharmacy or AB polypharmacy (784)
S3 TI beer* n1 criter* or AB beer* n1 criter* (113)
S4 TI (appropriate N2 medici* or optim* N2 medici* or inappropriat* N2 medici* or suboptim* N2 medici* or sub-optim*
N2 medici* or unnecessary N2 medici*or incorrect* N2 medici* or in-correct* N2 medici*or excess* N2 medici*or multip* N2
medici* or concurrent* N2 medici* ) or AB (appropriate N2 medici* or optim* N2 medici* or inappropriat* N2 medici* or suboptim*
N2 medici*or sub-optim* N2 medici* or unnecessary N2 medici*or incorrect* N2 medici* or in-correct* N2 medici*or excess* N2
medici*or multip* N2 medici* or concurrent* N2 medici* ) or TI (appropriate N2 medicat* or optim* N2 medicat* or inappropriat*
N2 medicat* or suboptim* N2 medicat* or sub-optim* N2 medicat* or unnecessary N2 medicat* or incorrect* N2 medicat* or in-
correct* N2medicat* or excess* N2medicat* or multip* N2medicat* or concurrent* N2medicat* ) or AB (appropriate N2medicat* or
optim* N2medicat* or inappropriat* N2medicat* or suboptim* N2medicat* or sub-optim* N2medicat* or unnecessary N2medicat*
or incorrect* N2 medicat* or in-correct* N2 medicat* or excess* N2 medicat* or multip* N2 medicat* or concurrent* N2 medicat* )
or TI ( appropriate N2 prescription* or optim* N2 prescription* or inappropriat* N2 prescription* or suboptim* N2 prescription* or
sub-optim* N2 prescription* or unnecessary N2 prescription* or incorrect* N2 prescription* or in-correct* N2 prescription* or excess*
N2 prescription* or multip* N2 prescription* or concurrent* N2 prescription* ) or AB (appropriate N2 prescription* or optim* N2
prescription* or inappropriat* N2 prescription* or suboptim* N2 prescription* or sub-optim* N2 prescription* or unnecessary N2
prescription* or incorrect* N2 prescription* or in-correct* N2 prescription* or excess* N2 prescription* or multip* N2 prescription*
or concurrent* N2 prescription* ) or TI (appropriate N2 drug* or optim* N2 drug* or inappropriat* N2 drug* or suboptim* N2 drug*
or sub-optim* N2 drug* or unnecessary N2 drug* or incorrect* N2 drug* or in-correct* N2 drug* or excess* N2 drug* or multip* N2
drug* or concurrent* N2 drug* ) or AB ( inappropriat* N2 drug* or suboptim* N2 drug* or sub-optim* N2 drug* or unnecessary N2
drug* or incorrect* N2 drug* or in-correct* N2 drug* or excess* N2 drug* or multip* N2 drug* or concurrent* N2 drug* ) (2,747)
S5 TI (over n2 prescript* or overprescrib* or overprescript* ) or AB (over n2 prescript* or overprescrib* or overprescript* ) (369)
S6 TI (”under prescript*“ or underprescrib* or underprescript* ) or AB (”under prescript*“ or underprescrib* or underprescript*
) (55)
S7 TI ”medication appropriateness index*“ or AB ”medication appropriateness index*“ (19)
S8 TI (quality n2 prescription* or quality n2 medication* ) or AB (quality n2 prescription* or quality n2 medication* ) (234)
S9 TI (improv* n2 prescription* or improv* n2 pharmaco* ) or AB (improv* n2 prescription* or improv* n2 pharmaco* ) (458)
S10 TI ”Assessing care of vulnerable elders“ or AB ”Assessing care of vulnerable elders“ (31)
S11 TI acove or AB acove (20)
46Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S12 TI ( multi-drug* N3 therap* or multi-drug* N3 treatment or multi-drug* N3 regime*) or AB ( multi-drug* N3 therap* or
multi-drug* N3 treatment or multi-drug* N3 regime*) or TI (multidrug* N3 therap* or multidrug* N3 treatment or multidrug* N3
regime*) or AB (multidrug* N3 therap* or multidrug* N3 treatment or multidrug* N3 regime*) (236)
S13 MHMedication Errors (7,779)
S14 TI (pharmaceutical* or prescribing) or AB (pharmaceutical* or prescribing) (13,361)
S15 MH Pharmacists (4,050)
S16 (MH ”Pharmacy Technicians“) (175)
S17 (MH ”Drugs, Prescription“) (9,130)
S18 (MH ”Prescriptions, Drug“) (3,631)
S19 (MH ”Pharmacy Service“) or (MH ”Pharmaceutical Care“) (2,408)
S20 TI pharmacist* or AB pharmacist* (4,235)
S21 (MH ”Medication Management (Iowa NIC)“) OR (MH ”Medication Managements (Iowa NIC) (Non-Cinahl)“) (2)
S22 MH drug toxicity (2,766)
S23 TI (stopp or start screening tool) or AB (stopp or start screening tool) (18)
S24 TI ”Screening Tool of Older Person’s Prescriptions“ or AB ”Screening Tool of Older Person’s Prescriptions“ (0)
S25 TI ”Screening Tool to Alert doctors to Right Treatment“ or AB ”Screening Tool to Alert doctors to Right Treatment“ (2)
S26 TI medication* N2 management or AB medication* N2 management or TI medication N2 review* or AB medication N2
review* or TI medication* N2 strateg* or AB medication* N2 strateg* (1,888)
S27 TI pharmacotherap* or AB pharmacotherap* (3,118)
S28 (MH ”Drug Therapy“) (4,741)
S29 (MH ”Drug Utilization“) (3,385)
S30 TI ”drug utili*ation“ N2 review* or AB ”drug utili*ation“ N2 review* or TI ”drug utili*ation“ N2 evaluat* or AB ”drug
utili*ation“ N2 evaluat* (64)
S31 MH drug monitoring (3,216)
S32 TI ”drug regimen review*“ or AB ”drug regimen review*“ (11)
S33 ”case conferencing“ (18)
S34 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or
S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 (54,600)
S35 TI ”homes for the aged“ or AB ”homes for the aged“ or MH Housing for the elderly (1,713)
S36 TI (care W1 home*) or AB (care W1 home*) or TI (care W1 center*) or AB (care W1 center*) or TI (care W1 centre*) or AB
(care W1 centre*) or TI ( care W1 facilit*) or AB ( care W1 facilit* ) or TI (convalescent W1 home*) or AB (convalescent W1 home*)
or TI (convalescent W1 center*) or AB (convalescent W1 center*) or TI (convalescent W1 centre*) or AB (convalescent W1 centre*)
or TI ( convalescent W1 facilit*) or AB ( convalescent W1 facilit* ) (13,654)
S37 (MH ”Hospitals, Veterans“) (2,768)
S38 MH Nursing Homes+ or MW Nursing Home (30,352)
S39 TI skilledW1 ”nursing facilit*“ or AB skilledW1 ”nursing facilit*“ or TI intermediateW1 ”nursing facilit*“ or AB intermediate
W1 ”nursing facilit*“ (788)
S40 TI aged N2 ”care facilit*“ or AB aged N2 ”care facilit*“ or TI aged N2 ”care home*“ or AB ”aged care home*“ or TI aged N2
”nursing facilit*“ or AB aged N2 ”nursing facilit*“ or TI ”aged nursing home*“ or AB ”aged nursing home*“ or TI aged N1 ”healthcare
facilit*“ or AB aged N1 ”healthcare facilit*“ (374)
S41 TI resident* N2 care or AB resident* N2 care or TI resident* N2 facilit* or AB resident* N2 facilit* (4,317)
S42 TI ( nursing N1 home* or group N1 home* or residential N1 home* ) or AB ( nursing N1 home* or group N1 home* or
residential N1 home* ) (14,133)
S43 TI aged N2 ”residential facilit*“ or AB aged N2 ”residential facilit*“ or TI ”aged residential home*“ or AB ”aged residential
home*“ or Ti geriatric N2 facilit* or AB geriatric N2 facilit* or TI geriatric* N1 ”care home*“ or AB geriatric* N1 ”care home*“ or TI
elderly N2 facilit* or AB ”elderly facilit*“ or Ti elderly N2 ”care home*“ or AB elderly N2 ”care home*“ (188)
S44 TI ( longterm N3 care or longterm N3 facilit* ) or AB ( longterm N3 care or longterm N3 facilit* ) or TI ( long-term N3 care
or long-term N3 facilit* ) or AB ( long-term N3 care or long-term N3 facilit* ) (9,794)
S45 MH Residential Facilities or MH Long Term Care (17,180)
S46 ”residential home*“ or healthcare N2 facilit* (1,263)
S47 MH Assisted Living (1,674)
S48 TI ”Assisted Living“ or AB ”Assisted Living“ (1,179)
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S49 TI ( ”life care cent*“ or ”continued care cent*“ or ”extended care facilit*“ ) or AB ( ”life care cent*“ or ”continued care cent*“
or ”extended care facilit*“ ) (143)
S50 (MH ”Halfway Houses“) (91)
S51 S36 or S39 or S41 or S42 or S44 or S45 or S46 or S47 or S48 or S49 or S50 (45,450)
S52 (MH ”Aged+“) (296,100)
S53 MH Geriatrics (2,120)
S54 TI ( ageing or aging or gerontol* or elder* or geriatric* or seniors or ”old age“ or ”late* life“ ) or AB ( ageing or aging or
gerontol* or elder* or geriatric* or seniors or ”old age“ or ”late* life“ ) (70,753)
S55 TI ( old* N1 person* or old N1 people or old N1 adult* or old N1 patient* or old N1 inpatient* or old N1 outpatient* ) or
AB ( old* N1 person* or old N1 people or old N1 adult* or old N1 patient* or old N1 inpatient* or old N1 outpatient* ) (6,592)
S56 MH veterans (5,462)
S57 TI veterans or AB veterans (5,981)
S58 (S35 or S37 or S38 or S40 or S43) (34,427)
S59 S52 or S53 or S54 or S55 or S56 or S57 (323,035)
S60 S51 and S59 (21,251)
S61 S58 or S60 (45,614)
S62 (MH ”Clinical Trials“) (76,194)
S63 PT clinical trial (51,892)
S64 TX clinic* n1 trial* (109,676)
S65 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) (541,676)
S66 TX ”randomi* control* trial*“ (33,534)
S67 MH Random Assignment (28,601)
S68 TX ”random* allocat*“ (2,249)
S69 MH Quantitative Studies (8,242)
S70 TX ”allocat* random*“ (111)
S71 S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70 (647,032)
S72 S34 and S61 and S71 (407)
International Pharmaceutical Abstracts, 1980-, OvidSP
Search run 16th November 2012
Number of results: 703
1 polypharm*.ti,ab,hw. (810)
2 (beer* adj1 criter*).ti,ab,hw. (108)
3 ((appropriate or optim* or adverse or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct*
or excess* or multip* or concurrent*) adj2 (medicine? or medication? or prescription* or drug*)).ti,ab,hw. (25362)
4 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,ab,hw. (17859)
5 ((under adj1 prescript*) or (underprescrib* or underprescript*)).ti,ab,hw. (17835)
6 medication appropriateness index*.ti,ab,hw. (34)
7 (quality adj1 (prescription* or medication*)).ti,ab,hw. (237)
8 (improv* adj1 (prescription* or pharmaco*)).ti,ab,hw. (339)
9 prescrib*.ti,ab,hw. (17663)
10 Assessing care of vulnerable elders.ti,ab. (2)
11 acove.ti,ab. (0)
12 ((multi-drug* or multidrug*) adj2 (therapy or therapies or treatment or regime*)).ti,ab,hw. (217)
13 Medication Error?.ti,ab,hw. (3154)
14 pharmaceutical*1.ti,ab. (32258)
15 pharmacist*.ti,ab,hw. (47739)
16 (pharmacy adj (technician? or aide?)).ti,ab,hw. (1661)
17 (Prescription adj2 drug?).ti,ab,hw. (4857)
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18 Drug distribution system?.ti,ab,hw. (1890)
19 (medication? management ormedication? therapymanagement ormedication? strategy ormedication? strategies or (medication?
adj2 review?)).ti,ab,hw. (1868)
20 drug toxicity.ti,ab,hw. (456)
21 Screening Tool of Older Person’s Prescriptions.ti,ab. (3)
22 Screening Tool to Alert doctors to Right Treatment.ti,ab. (6)
23 (pharmaceutical adj (preparation? or care)).ti,ab,hw. (7739)
24 pharmacotherap*.ti,ab,hw. (3820)
25 drug therap*.ti,ab,hw. (8197)
26 (drug adj utili?ation adj2 (review* or evaluat*)).ti,ab,hw. (4848)
27 drug monitoring.ti,ab,hw. (1813)
28 drug regimen review*.ti,ab,hw. (194)
29 case conferencing.ti,ab,hw. (0)
30 or/1-29 [Prescribing/medication terms] (122563)
31 Home? for the Aged.ti,ab,hw. (13)
32 (aged adj2 (care or nursing or healthcare or residential) adj2 (facility or facilities or home?)).ti,ab,hw. (30)
33 ((geriatric or elderly) adj2 (facility or facilities or care home?)).ti,ab,hw. (44)
34 or/31-33 [Aged care homes] (82)
35 ((skilled or intermediate) adj nursing facilit*).ti,ab,hw. (207)
36 (resident* adj2 (care or facilit*)).ti,ab. (371)
37 ((nursing or group or residential) adj home?).ti,ab. (1296)
38 ((longterm or long term) adj3 (care or facilit*)).ti,ab. (1407)
39 residential home?.ti,ab,hw. (52)
40 assisted living.ti,ab,hw. (101)
41 (life care cent* or continued care cent* or extended care facilit*).ti,ab,hw. (64)
42 Halfway house*.ti,ab. (3)
43 or/31-40 [Other residential care] (2911)
44 (ageing or aging or gerontol* or elder* or geriatric* or seniors or old age or late? life).ti,ab,hw. (13967)
45 (old* adj (person* or people or adult* or patient* or inpatient* or outpatient*)).ti,ab. (3200)
46 veteran*.ti,ab. (1377)
47 or/44-46 [Elderly terms] (17017)
48 43 and 47 (1089)
49 30 and (34 or 48) (720)
50 limit 49 to yr=”1980 -Current“ (703)
PsycINFO, 1980-, OvidSP
Search run 19th November 2012 [Database last updated November, week 2, 2012]
Number of results: 905
1 Polypharmacy/ (639)
2 polypharm*.ti,ab. (1043)
3 (beer* adj1 criter*).ti,ab. (57)
4 ((appropriate or optim* or adverse or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct*
or excess* or multip* or concurrent*) adj2 (medicine? or medication? or prescription* or drug*)).ti,ab. (3911)
5 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,ab. (136)
6 ((under adj1 prescript*) or (underprescrib* or underprescript*)).ti,ab. (35)
7 medication appropriateness index*.ti,ab. (14)
8 (quality adj1 (prescription* or medication*)).ti,ab. (39)
9 (improv* adj1 (prescription* or pharmaco*)).ti,ab. (94)
10 (drug related problem? or (prescription adj2 pattern?)).ti,ab. (509)
11 Assessing care of vulnerable elders.ti,ab. (37)
12 acove.ti,ab. (25)
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13 ((multi-drug* or multidrug*) adj2 (therapy or therapies or treatment or regime*)).ti,ab. (57)
14 Medication Errors.ti,ab. (259)
15 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. (23625)
16 Pharmacists/ (721)
17 (pharmacy adj (technician? or aide?)).ti,ab. (14)
18 Prescription Drugs/ (2137)
19 drug therapy/ (97624)
20 ”Prescribing (Drugs)“/ (2486)
21 medication? related problem?.ti,ab. (35)
22 stopp.ti,ab. (12)
23 (medication? management or medication? therapymanagement or medication strategy or medication? strategies or (medication
adj2 review?)).ti,ab. (1031)
24 Toxicity/ (2181)
25 start screening tool.ti,ab. (3)
26 Screening Tool of Older Person’s Prescriptions.ti,ab. (4)
27 Screening Tool to Alert doctors to Right Treatment.ti,ab. (3)
28 (medication adj2 (management or review*)).ti,ab. (1136)
29 pharmacotherap*.ti,ab. (9354)
30 ((drug adj utili?ation adj2 (review* or evaluat*)) or drug related problem?).ti,ab. (353)
31 Monitoring/ (4623)
32 drug regimen review*.ti,ab. (3)
33 case conferencing.ti,ab. (22)
34 or/1-33 [Medication or prescribing terms] (126093)
35 Treatment Facilities/ (947)
36 Homes for the Aged.ti,ab. (168)
37 (aged adj2 (care or nursing or healthcare or residential) adj2 (facility or facilities or care home?)).ti,ab. (192)
38 ((geriatric or elderly) adj2 (facility or facilities or care home?)).ti,ab. (121)
39 exp Nursing Homes/ (6128)
40 or/36-39 [Aged care facilities tems] (6489)
41 ((care or convalescent) adj (home? or center? or centre*? or facility or facilities)).ti,ab. (6787)
42 ((skilled or intermediate) adj nursing facilit*).ti,ab. (292)
43 (resident* adj2 (care or facilit*)).ti,ab. (4850
44 ((nursing or group or residential) adj home*).ti,ab. (9558)
45 Long Term Care/ (2840)
46 ((longterm or long term) adj3 (care or facilit*)).ti,ab. (5467)
47 Residential Care Institutions/ (7893)
48 residential home*.ti,ab. (376)
49 Assisted Living/ (457)
50 assisted living.ti,ab. (675)
51 (life care cent* or continued care cent* or extended care facilit*).ti,ab. (56)
52 Halfway Houses/ (271)
53 or/41-52 [Other care homes] (28264)
54 exp Aging/ (33115)
55 Geriatrics/ (6190)
56 Geriatric Patients/ (10088)
57 Gerontology/6870
58 (gerontol* or ageing or aging or elder* or geriatric* or seniors or ”old age“ or older or late* life).ti,ab. (157409)
59 (old* adj (person* or people or adult* or patient* or inpatient* or outpatient*)).ti,ab. (41520)
60 veteran*.ti,ab. (11445)
61 or/54-60 [Aged terms] (176363)
62 53 and 61 (9117)
63 34 and (40 or 62) (921)
64 limit 63 to yr=”1980 -Current“ (905)
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Web of Science, Conference Proceedings Citation Index- Science, 1990-, (ISI Web of Knowledge)
Search run 16th November 2012
Number of results: 50
#1 Topic=(polypharm* or (beer* SAME criter*)) OR Topic=((((inappropriat* or suboptim* or sub-optim* or unnecessary or
incorrect* or in-correct* or excess* or multip* or concurrent*) SAME (medici* or medicat* or prescrib* or prescription* or drug*))))
OR Topic=((((over SAME (prescrib* or prescript*)) or (overprescrib* or overprescript*)))) OR Topic=((((under SAME (prescrib* or
prescript*)) or (underprescrib* or underprescript*)))) OR Topic=((medication appropriateness index*)) OR Topic=(((quality SAME
(prescribing or prescription* or medication*)))) OR Topic=(((improv* SAME (prescrib* or prescription* or pharmaco*)))) OR Topic=
((prescrib* SAME cascade*)) (19750)
#2 Topic=(Assessing care of vulnerable elders) OR Topic=(acove) OR Topic=((multi-drug* or multi drug or multidrug*)) OR
Topic=(Medication Errors) OR Topic=(pharmaceutical preparations) OR Topic=((pharmaceutical or pharmaceuticals)) OR Topic=
((pharmacist* or pharmacy technician*)) OR Topic=(Prescription Drugs or Drug Prescriptions) OR Topic=(medication therapy man-
agement) OR Topic=(drug toxicity) OR Topic=(stopp start) OR Topic=(Screening Tool of Older Person’s Prescriptions) OR Topic=
(Screening Tool to Alert doctors to Right Treatment) OR Topic=((medication SAME (management or review*))) OR Topic=((pharma-
cotherap*)) OR Topic=(drug therapy) OR Topic=((drug utili?ation SAME (review* or evaluat*))) OR Topic=(drug monitoring) OR
Topic=(drug regimen review*) OR Topic=(case conferencing) (31664)
#3 #2 OR #1 (46729)
#4 TS=(”homes for the aged“) OR TS=((”care home“ or ”convalescent home“ or ”care center*“ or ”convalescent center*“ or
”care centre*“ or ”convalescent center*“ or ”care facilit*“ or ”convalescent facilit*“)) OR TS=((”nursing home*“ or ”group home*“ or
”residential home*“)) OR TS=((”skilled nursing facilit*“ or ”intermediate nursing facilit*“)) OR TS=(”aged care facilit*“) OR TS=
(resident* SAME (care or facilit*)) OR TS=(((longterm or long term or long-term) SAME (care or facilit*))) OR TS=(”assisted living“)
OR TS=((”life care cent*“ or ”continued care cent*“ or ”extended care facilit*“)) OR TS=(Halfway houses) (13434)
#5 TS=((aged or elder* or geriatric* or seniors or ”old age“ or older or ”late* life“)) OR TS=((”old* person*“ or ”old* people“ or
”old* adult*“ or ”old* patient*“ or ”old* inpatient*“ or ”old* outpatient*“)) OR TS=(”veteran*“) (68647)
#6 TS=(random* or RCT*) (152549)
#7 #6 AND #5 AND #4 AND #3 Databases=CPCI-S, CPCI-SSH Timespan=1990-01-01 - 2012-11-28
Lemmatization=Off (50)
Appendix 2. Google scholar search strategy
Searched 16th November 2012
Number of results: 59
(prescription* or prescribing or drug* or medicine* or medication* or pharma* or polypharmacy) and (residential or care home* or
care facilit* or nursing home*) and (elder* or aged* or old* or seniors or geriatric* or gerontol*) Books excluded. No date limit.
Appendix 3. WHO trial registry search strategy
Search run 26th November 2012 [Database last updated 26th November 2012]
Number of results: 2
Each term 1 was searched with each possible combination of the other terms (2-4). Terms were combined using AND
Term 1 Term 2 Term 3 Term 4
Randomised Nursing homes elderly drugs
Randomized Residential homes old medication
RCT pharmacy
Randomly polypharmacy
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S O U R C E S O F S U P P O R T
Internal sources
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External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We intended to pool results and conduct meta-analyses if studies were homogeneous. However, as studies were heterogeneous, this was
not undertaken. Similarly, subgroup analyses were not possible.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Homes for the Aged; ∗Nursing Homes; Drug Prescriptions [∗standards]; Inappropriate Prescribing [∗prevention & control]; Medica-
tion Reconciliation; Quality Improvement [∗standards]; Randomized Controlled Trials as Topic
MeSH check words
Aged; Humans
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